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ABSTRACT 
Polypharmacy is a healthcare problem of epidemic proportions in the United States.  It is 
frequently associated with negative health outcomes in the lives of both elderly and chronically 
ill persons at excessive costs to the United States healthcare system.  Appropriate medication 
management incorporating evidence-based guidelines is essential to addressing polypharmacy.  
Prescribing clinicians in all disciplines have expressed a lack of confidence and perceived gaps 
in knowledge to address polypharmacy through deprescribing.  This scholarly project aimed to 
determine if a polypharmacy protocol intervention, based on the most current evidence-based 
guidelines in prescribing and deprescribing, would improve clinician confidence in the decision 
making to reduce polypharmacy and increase ability to recognize potentially inappropriate 
medications and potentially inappropriate prescribing omissions.  The scholarly project utilized a 
quasi-experimental study design with pre-intervention and post-intervention data collection using 
the Clinician Polypharmacy Management Survey.  Evaluation of the data demonstrated a 
clinically significant increase in clinician confidence and ability in the recognition of 
polypharmacy and capability to prescribe and deprescribe following the implementation of the 
protocol.  Although not as strong statistically, all ten areas of confidence measured, demonstrated 
improvement.  The results of the scholarly project agreed with the literature that implementation 
of evidence-based guidelines for prescribing and deprescribing increases clinician confidence in 
addressing polypharmacy.   
Keywords:  Polypharmacy, deprescribing, evidence-based guidelines, confidence, 
potentially inappropriate medications, clinician 
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Introduction: Polypharmacy 
Polypharmacy is defined as the regular use of multiple medications, either prescribed, over-
the-counter (OTC), or a combination.  The incidence of polypharmacy most often occurs in 
persons receiving treatment for one or more chronic disease (Masnoon, Shakib, Kalisch-Ellett, 
and Caughey, 2017).  Because of the correlation between polypharmacy and chronic diseases, 
older adults, by a significant percentage, have the highest prevalence of polypharmacy compared 
to other age groups.  A number of concerning outcomes for elderly persons have been associated 
with polypharmacy, even after adjusting for chronic conditions.  Research has shown these 
negative outcomes to include falls, adverse drug reactions, morbidity, increased length of 
hospital stays, and frequent readmissions to the hospital (Masnoon et al., 2017).  Appropriate 
medication management is essential to decreasing polypharmacy, beginning with the education 
of all prescribing healthcare providers and continuing with up-to-date evidence-based guidelines 
usage by prescribing clinicians in the practice setting (Djerbib, 2018; Kostas et al., 2014; Martin, 
Tamblyn, Benedetti, Ahmed, and Tannenbaum, 2018).  The general discomfort with reducing 
polypharmacy through deprescribing, by healthcare providers at all levels of experience, 
validates the need for evidence-based methods to address the situation (Djerbib, 2018; Farrell et 
al., 2018; Mecca et al., 2019).  The incorporation of prescribing and deprescribing solutions into 
practice is crucial for proper medication management by clinicians. 
Background 
Although there was inconsistency in the literature on the characterization of polypharmacy, 
research by Masnoon, et al. (2017), determined the most commonly used definition for 
polypharmacy as regular use of five or more medications.  The definition of older adults or 
elderly persons also varied in the literature.  While the age of 65 or older was the most common, 
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it should be noted the youngest age included in the research is 50.  For the purpose of the 
scholarly project, older adults/elderly was defined as 65 years of age or older.    
Related to the high prevalence of chronic disease in the elderly, polypharmacy has been a 
rapidly increasing problem the last several years.  In the United States (US), the prevalence of 
co-morbidities of two or more chronic diseases was 61% in the elderly population (Quinn & 
Shah, 2017).  This frequency of chronic disease and the associated medical treatment resulted in 
30% of elderly persons in the US with medication regimes reflecting polypharmacy (Quinn & 
Shah, 2017).  The US is not alone in the high rate of polypharmacy, as similar incidence has 
been reported in many European countries, Australia, Japan, China, Brazil, Canada, and India.  
The problem of polypharmacy has been seen in primary care, in-home healthcare settings, adult 
long-term care facilities, and acute care hospitals.   
An equally concerning situation and related cause for polypharmacy, has been the number 
of inappropriate drugs prescribed for the elderly, known as potentially inappropriate medications 
(PIMs) and potentially inappropriate prescribing omissions (PPOs).  The occurrence of PIMs has 
been estimated to be as high as 50% in the elderly population (Kua, Mak, & Huey Lee, 2019).  
According to Kimura et al. (2016), PIMs are prescribed medications that involve an incorrect 
dose, frequency, or mode of administration; the duration of treatment is incorrect; high risk of 
clinically significant drug-drug or drug-disease interactions; or without a clear evidence-based 
clinical indication.  PPOs are medications that are clinically indicated for the treatment of a 
certain condition or disease, or used to prevent disease in persons at risk.  The incidence of 
polypharmacy increases the risk for both PIMs and PPOs in the elderly population.  The elderly 
in the US were found to use 33% of all prescription medications and account for 40% of the 
OTC drugs, supplements, and herbals.  The percent of adults 65 or older was estimated to be 
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15% of the US’ population in 2014, with an estimated growth to 21% by 2030 (Mather, 
Jacobsen, & Pollard, 2015).  Related to these projections, healthcare concerns for polypharmacy, 
PIMs, and PPOs will continue to be a growing problem in the US.   
According to Quinn and Shah (2017) the prevalence of polypharmacy related drug 
reactions have been responsible for the acute care hospitalization of 4 of every1000 people each 
year, was among the ten most common causes of death, and was estimated to cost the healthcare 
system in the US upwards of $180 billion dollars annually.  For the elderly population, the 
burden of adverse drug effects and interactions were highest with 10-15% of all hospital 
admissions in this age group related to an adverse drug effect (Löffler, et al., 2014).  In addition 
to increased hospitalization, it’s estimated 23% of nursing home admissions in the US were 
related to problems the elderly patient experience because of polypharmacy (Pasina et al., 2014).  
The data suggests polypharmacy increased the risk of falls, frailty, physical and cognitive 
dysfunction, which has lead to loss of autonomy and decreased quality of life for the elderly 
population (Muth et al., 2018).  The far-reaching effects of polypharmacy with the immense 
negative impact on the lives of elderly persons and the exorbitant costs to the healthcare system 
is an issue that needs to be addressed at all levels of patient care. 
The need for enhanced awareness to address polypharmacy and medical management 
within primary care in the US is recognized in the research, but implementation of evidence-
based solutions has been limited and inconsistent (Campins et al., 2017; Djerbib, 2018; Mecca et 
al., 2019).  Clinicians in multiple disciplines, including physicians, nurse practitioners, and 
physician assistants, have expressed discomfort with their ability to address polypharmacy 
through deprescribing.  There are perceived gaps in their training, knowledge, and resources to 
effectively prioritize care when patients have multiple comorbidities coupled with polypharmacy 
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(Djerbib, 2018; Farrell et al., 2018; Mecca et al., 2019).  Numerous reasons for clinicians’ lack of 
confidence in addressing polypharmacy were identified, including: concerns for withdrawal, 
ability to monitor, stopping or changing a medications prescribed by another provider, lack of 
clarity related to tapering, failure in disease management, and other adverse side effects (Farrell 
et al., 2018).   
Polypharmacy can be appropriate and justified when treating patients with multiple 
comorbidities.  The challenge for the prescriber is achieving a balance between minimizing the 
risks and adverse effects of polypharmacy, while maintaining optimal control of chronic disease 
symptoms and progression.  The situation is further complicated when patient or families are 
resistant to changes or there is poor adherence to current medication regimen. 
An evidence-based reduction in the number of long-term medications has shown to 
decrease acute hospital length of stays and admissions, improve mortality, and reduce the 
healthcare costs to individuals and the healthcare system (Löffler, et al., 2014).  Several criteria 
have been successfully used for reducing the burden of polypharmacy and detecting PIMs and 
PPOs.  The most common methods included the Beers Criteria, Improved Prescribing in the 
Elderly Tool, and the Screening Tool of Older Persons’ Potentially Inappropriate 
Prescriptions/Screening Tool to Alert Doctors to Right Treatment (STOPP/START) criteria 
(Campins et al., 2017).  Other research has confirmed the simplification of medication regimens 
improved adherence and resulted in higher levels of patient satisfaction (Löffler, et al., 2014).   
Implementing an evidence-base intervention aimed to improve competency of primary care 
providers in medication management and polypharmacy has demonstrated success in the 
research (Campins et al., 2017; Djerbib, 2018; Farrell et al., 2018; Kostas et al., 2014).  Studies 
by Cossette et al. (2016) and Kostas et al. (2014) revealed deprescribing tools that improved 
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clinical judgment and guided decision-making, enhanced the learning experiences.  Other 
preferred methods included concise presentations that emphasized the relevance of a focused 
educational topic, such as deprescribing, and applying the specific information to patient care 
(Cossette et al., 2016).  Proper training and resources increased prescribing clinicians’ 
confidence for developing and implementing changes to patient’s medication regimen addressing 
polypharmacy, PIMs, and PPOs.  An intervention to improve deprescribing and medication 
management in the primary care setting will provide clinicians with an evidence-based 
methodology and medication analysis tool that will increase competence in addressing 
polypharmacy.  A short learning session providing education on the deprescribing tool must be 
focused, with clear information on usage and implementation in the practice setting.  It is 
important the intervention is user-friendly, efficient, and effective at addressing polypharmacy 
through the reduction of PIMs, evaluation of PPOs, and takes into consideration patient 
preferences.  
Problem Statement 
Polypharmacy affects 30% of elderly persons in the US.  The burden of polypharmacy on 
the elderly population in the US is reflected in increased hospitalizations and nursing home 
admissions, decreased quality of life related to falls, cognitive and physical impairment, and 
increased mortality.  The additional cost to the US healthcare system for acute care hospital 
admissions alone was estimated at $180 billion dollars in 2014.  With the percentage of adults 65 
or older expected to increase 50% by the year 2030, the costs of polypharmacy to individuals and 
the society is a healthcare crisis in the US.  Primary care providers of all disciplines are in need 
of effective, easy to implement methods and tools to address polypharmacy management and 
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deprescribing.  To successfully address polypharmacy and reverse this worsening healthcare 
crisis in the US, the use of evidence-based protocols in primary care settings are crucial.  
Purpose of the Project 
The purpose of the scholarly project was to implement and evaluate the effects an 
evidence-based pocket-sized deprescribing tool had on primary care providers’ awareness and 
confidence in addressing polypharmacy, PIMs, and PPOs during outpatient visits.  The 
significance of the project was the clinician’s increased understanding and ability to identify and 
address polypharmacy during patient primary care visits.  The primary outcome was the affect a 
tool developed from evidence-based guidelines had on prescriber confidence in the deprescribing 
decision making process.  The secondary outcomes were a self-evaluation of skills in 
recognizing PIMs and PPOs, and increased confidence to deprescribe when specific, common 
barriers were encountered in the presence of polypharmacy. 
Clinical Question 
The clinical question was “Would primary care providers in an outpatient setting (P) with 
the utilization of an evidence-based deprescribing protocol to reduce polypharmacy (I), 
experience an increase in perceived awareness and confidence to initiate medication changes (O) 
compared to standard practice before the introduction of the protocol (C)?” 
Literature Review 
Search Strategy 
The search for literature began with the Jerry Falwell Library “Search Anything” box on 
the main page, delimited by the option of “Articles”.  Although separate searches were also 
performed using multiple databases (CINAHL Plus with Full, National Guideline Clearinghouse, 
Cochran Database of Systematic Reviews, ProQuest Nursing and Allied Health Database, 
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EBSCO, and PubMed), the results of the “Search Anything” function provided the best 
comprehensive search for the topic.  The general delimiters were English language, published in 
the last 5 years, journal articles only, and scholarly and peer-reviewed articles.  The search string 
terms of polypharmacy, elderly, research, clinical trial, intervention, PIMs, STOPP, education, 
learning preference, primary care, nurse practitioner, US, and deprescribing were used in various 
combinations resulting in 287 articles.  After reviewing the first 100 articles, with some chosen 
for the literature review and proposal, further refinement to the list was made by limiting articles 
to those published in the past 3 years with a resulting 127 journal articles.  Next, pilot studies, 
study protocols, poorly executed or reported studies, and studies that were not pertinent to the 
project were eliminated.  Because the project was based in the US with a Western cultural view 
of healthcare, the studies were limited to European countries, Australia, the US, Canada, and 
Japan.  Nineteen articles were chosen for the literature review.  
Critical Appraisal 
Review of the studies found seven articles with a 1 or 2 level of evidence using the Melnyk 
Framework, which were selected for inclusion (Melnyk & Fineout-Overholt, 2015).  An 
additional nine studies with a Melnyk level of evidence of 3 or 4, including a systemic review of 
cohort/case-control studies, were chosen for the strength of the studies as well as the contribution 
to the evidence and knowledge of the scholarly project subject (Melnyk & Fineout-Overholt, 
2015).  Finally, three more research studies with a level of evidence of 5 or 6 according to the 
Melnyk Framework (Melnyk & Fineout-Overholt, 2015) were chosen for their contribution to 
better understanding the importance of the patient in deprescribing and an analysis of the 
dynamics influencing the decision making process of primary care providers.  
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Reduction of polypharmacy, PIMs, and PPOs. 
A systemic review and meta-analysis by Kua et al. (2019) evaluated research studies 
related to polypharmacy and deprescribing, performed among elderly residents in nursing homes.  
A total of 41 randomized clinical studies were appraised for the research study, all matching the 
criteria of execution in a country with a Western culture.  Overall, deprescribing interventions 
reduced the number of PIMs by 59% (Kua et al., 2019).  Limitations in the Kua et al. (2019) 
study included: dissimilarities in reporting measures for the same patient outcomes, variation in 
outcomes measured among the studies, and some studies had a short study period.  This study 
provided strong evidence for deprescribing as an effective method to reduce PIMs.  Also, while 
there are a variety of methods used to accomplish deprescribing, a medication review 
intervention was the most successful in improving patient outcomes. 
In a random controlled trial (RCT) study by Campins et al. (2017), the STOPP/START 
criteria was used effectively to reduce the cost and burden of polypharmacy through 
deprescribing medications of recruited community dwelling older adults.  Evaluation of the 
intervention group revealed 26.5% of the prescription medications as PIMs, and a total 21.5% of 
the prescription medications were either discontinued, substituted, or dose adjusted (Campins et 
al., 2017).  Also, 95.6% of the intervention group had at least one recommended change to 
medications  (Campins et al., 2017).  Continued assessments at three, six, and twelve months 
showed the number of prescriptions per intervention patient was significantly lower compared to 
the control group (Campins et al., 2017).  Limitations in the Campins et al. (2017) research 
included potential contagion of groups, with physicians having patients in each arm of the study.  
The study by Clyne et al. (2016) was a mixed method study involving an RCT and a 
qualitative semi-structured interview.  A three-phase intervention was conducted in general 
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practitioner (GP) practices to reduce PIMs for older adults, and evaluated the execution and 
effectiveness of each of the three phases (Clyne et al., 2016).  Results found just over 70% of the 
practices completed the medication review with the patient present (Clyne et al., 2016).  Even so, 
the research demonstrated the effectiveness of the interventions to reduce PIMs in the elderly.  
Limitation involved the inability to capture a meaningful volume of qualitative data. 
Next, the RCT study by Martin et al. (2018) was a pharmacist-led intervention, with 
recommendations for deprescribing using the Beers Criteria sent to the physician and educational 
deprescribing brochure to the patient.  The study involved community pharmacies and recruited 
elderly patients each prescribed one or more Beers Criteria medications.  Evaluation at six 
months revealed 43% of the intervention group no longer received prescriptions for the PIMs, 
compared to 12% of the control group.  Two noted limitations, included the confounding change 
in guidelines calling for the discontinuation of glyburide, and the small recruitment of patients 
using nonsteroidal anti-inflammatory drugs (NSAIDs) or first generation antihistamines.  The 
association and reliability of using the Beers Criteria for deprescribing with positive patient 
outcomes, is strengthened. 
By trialing a computer decision support system in general practices, the RCT study by 
Muth et al. (2018), investigated if the intervention would show improvement in number of PIMs 
utilized by elderly with multiple co-morbidities.  While results of this study showed no 
significant changes in patient prescriptions, quality of life, or functional status, it should be noted 
both the control and intervention groups had few medications identified as PIMs, and high 
functional status and quality of life indicators at the beginning of the study.  Limitations included 
the Hawthorne effect with intense data collection at every visit, the lower age limit of 60 for 
participants, and an arbitrary definition of polypharmacy.  The study still provided important 
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outcomes to consider in the overall scope of the proposed project, especially involving the 
importance of limiting the prescribing of PIMs. 
The research study by Potter, Flicker, Page, and Etherton-Beer (2016) was a RCT aimed to 
reduce polypharmacy and PIMs usage by elderly in residential aged care facilities through 
medication reviews by a pharmacist and GP.  In the intervention group, 348 medications were 
identified for deprescribing, with a total of 207 (59%) medications successfully discontinued 
(Potter et al., 2016).  The primary limitations of the study were the small number of participants 
and an open design, which can lead to treatment bias.  Successfully deprescribing without 
adverse health outcomes evidenced the importance of this study. 
In the RCT study by Schäfer et al. (2018), the intervention involved three 30-minute 
consolations by the GP, expected to demonstrate a reduction in polypharmacy, without a 
negative affect on quality of life.  During the 12-month study, there was no statistically 
significant difference, between the intervention and control groups related to change in number 
of medications used or quality of life indicators (Schäfer et al., 2018).  The intervention group 
was twice as likely to receive a new prescription for an analgesic compared to the control group.  
Major study limitations were unobserved consults, study volunteers may have been more 
cooperative, and higher satisfaction with their GP compared to the population.  In the instance of 
this study, a high intensity intervention demonstrated a neutral impact on the degree of 
polypharmacy. 
Research by Van der Linden et al. (2017), was a quasi-experimental design study that 
assessed the effect of a pharmacist medications review with the application of the STOPP criteria 
to elderly patients’ home medications.  The patients were admitted to an acute geriatric ward in a 
university hospital.  The results of the study demonstrated the intervention group had more 
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medications discontinued at discharge, including a higher number of PIMs, compared to the 
control group.  Re-evaluation of both groups, 3 months after discharge, revealed patients in the 
intervention group continued to have less PIMs prescribed without adverse health events.  
Limitations of the study were lack of randomization and a follow-up period of only three months.  
The safe reduction of polypharmacy and PIMs in elderly patients with the use of the STOPP 
protocol demonstrated a positive effect on the quality of life. 
A cohort study completed by Kimura et al. (2017), evaluated the efficacy of a medication 
review by hospital pharmacists using the STOPP criteria to deprescribe PIMs in elderly patients.  
Of the participants in the study, 346 were identified as having one or more PIMs.  The 
intervention identified 310 PIMs to be discontinued, resulting in a total of 292 PIMs either 
discontinued or modified (Kimura et al. (2017).  Limitations of the study included 
generalizability, initial reasons for prescribing of PIMs were not considered for deprescribing, 
and no evaluation of patient outcomes with discontinuation of PIMs.  The research demonstrated 
prescribing of PIMs to be a significant problem in the elderly and can be effectively addressed 
using tools that are currently available. 
The next study was a correlational design cohort study by Komagamine and Hagane (2017) 
that evaluated the effectiveness of an internal medicine physician medication assessment, for 
patients admitted with hip fractures.  The intervention considered evidence-based use for the 
medication, valid indication related to age and disability level, harm versus benefits, and 
availability of a superior medication or non-pharmacological treatment (Komagamine & Hagane, 
2017).  The total prescribed PIMs was statistically lower at discharge in the intervention group.  
No significant differences were observed in clinical outcomes at the six-month follow-up 
comparing the intervention and control group.  Limitations were related to the study’s 
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retrospective observational design, no follow-up for adverse reactions, and long-term outcomes.  
Including only a special subset of patients may dilute the real effects of the interventions.  Even 
with the limitations, the study showed deprescribing an effective approach to reducing PIMs. 
The quasi-experimental cohort study by Urfer, Elzi, Dell-Kuster, and Bassetti (2016), 
assessed the safety and efficacy of a prescriber checklist using the STOPP/START criteria for 
reducing polypharmacy and PIMs and addressing PPOs.  The study involved elderly patients 
hospitalized in the internal medicine wards.  At admission and evaluation of both control and 
intervention groups, 59% had medication regimens reflecting polypharmacy, 37% had one, or 
more PIMs and 25% had one or more PPOs (Urfer et al., 2016).  The intervention arm of the 
study demonstrated a 22% reduction in PIMs at discharge.  In addition, there was an overall 
decrease in the number of total prescription medications at discharge, but less than the 20% 
theorized, and the reduction of PPOs at discharge was lower than expected (Urfer et al., 2016).  
The primary limitations experienced by the study are reduced strength of evidence compared to 
an RCT, and decreased generalizability related to a single site study.  The strength of this study 
is an easy to use intervention producing a significant reduction in PIMs at discharge. 
Association of polypharmacy and adverse outcomes.  
Fried et al. (2014) conducted a systematic review of fifty observational studies, with four 
case-control studies and the rest identified as cross-sectional or longitudinal cohort studies.  The 
purpose of the research was to summarize the health outcomes associated with polypharmacy in 
elderly community-dwelling persons.  Results revealed the majority of the studies receiving a 
good rating, in terms of adjustment for comorbidities, demonstrated a significant relationship 
between polypharmacy and adverse outcomes.  The adverse outcomes patients experienced were 
comprised of increased fall risk factors, falls, negative fall outcomes, patient decreased function 
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and cognition, and adverse drug events resulting in drug interactions, hospitalizations, and 
mortality (Fried et al., 2014).  The strongest relationship was falls associated with polypharmacy 
in the better-rated studies.  A few inconsistent results occurred with some studies rated as good 
that did not reveal a relationship between polypharmacy and adverse effects.  Also, some studies 
rated as fair or poor, in terms of adjustments for comorbidities, did indicate an association 
between adverse effects and polypharmacy.  Limitations identified were heterogeneity in the 
study populations and differing definitions of polypharmacy that made direct comparisons 
between studies very challenging (Fried et al., 2014).  Relevant studies were likely missed 
considering many were found through reference lists, rather than database searches.  A wide-
variety in types of medications included or excluded was identified among the studies.  Overall, 
a definitive association could not be made between polypharmacy and the adverse events listed 
above, but there were good associations and when considered along with other research, this 
study does support the relationship. 
Patient secondary outcomes. 
In the systemic review by Kua et al. (2019), the results showed that even with variety in 
reporting, deprescribing had significant impact on patient outcomes.  Further analysis of the data 
comparing the different type of deprescribing interventions, a medication review-directed 
intervention was shown to reduce the number of residents experiencing falls by 24% and all-
cause mortality reduced by 26% (Kua et al., 2019).  The Martin et al., (2018) RCT was 
significant for no adverse events requiring hospitalization within the intervention group at the 
six-month evaluation after deprescribing.  In the Potter et al. (2016) study the intervention group 
showed improved mortality at the 12-month evaluation.  Other secondary outcomes studied: 
fractures, falls, hospital admissions, sleep, bowel function, physical function, cognition, quality 
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of life; had no significant differences between the intervention and control groups, possibly 
influenced by the number of study participants (Potter et al., 2016).  The Schäfer et al. (2018) 
RCT displayed the number of hospital days was reduced in the intervention group but did not 
effect the degree of polypharmacy in the intervention group.  At three months post-discharge in 
the Van der Linden et al. (2017) study, the safe reduction of polypharmacy and PIMs in elderly 
patients in the intervention arm showed a positive effect on quality of life, including a downward 
trend in emergency department visits and hospital readmission, compared to the control group.  
Not all studies had the sample size necessary to properly assess secondary outcomes.  In 
the RCT by Campins et al. (2017), the sample size was small with limited statistical power for 
the evaluation of secondary outcomes for emergency department visits, hospitalizations, and 
deaths.  Another study producing no significant results was the Muth et al. (2018) RCT, where 
the patient population in both arms had a small occurrence of polypharmacy and PIMs.  
Furthermore, studies by Clyne et al. (2016), Kimura et al. (2017), Komagamine and Hagane 
(2017), and Urfer et al. (2016) did not perform measurements on secondary outcomes.  
Patient participation. 
Many studies identified the importance of patient participation in the deprescribing process.  
The study by Clyne et al. (2016) demonstrated changes to current medication regimens were 
more successful when the patient was present, reinforcing the importance of patient participation.  
Research by the Martin et al. (2018) also strengthened the concept when patient education was 
proven to be critical for deprescribing PIMs.  The study by Komagamine and Hagane (2017), 
employed a protocol where the physician involved the patient or caregiver in the decision 
making process for deprescribing.   
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The next two research studies although qualitative studies, add significant knowledge to the 
subject of polypharmacy and patient point of view.  The study by Pasina et al. (2014) aimed to 
describe adherence to medication regimen in elderly patients identified with polypharmacy after 
hospital discharge.  Participants were contacted for telephone interviews at 2-4 weeks and three 
months after discharge.  Results of the first follow-up call reflected patient non-adherence to 
medication regimens at 55.1% and at the second follow-up call, the non-adherence rate rose to 
69.9% (Pasina et al., 2014).  Furthermore, only 28.1% of patients reported understanding the 
reasons for their medications during the first call, and decreased to 25.3% during the second call 
at three month (Pasina et al., 2014).  Limitations include small sample size, overestimation of 
adherence from self-reporting, and no information collected for clinical outcomes associated 
with non-adherence.  The information revealed by the study provided a strong rational to reduce 
polypharmacy and simplify elderly patients’ medication regimens.  Also, the need for patient 
friendly education, better communication related to medication importance, and the need for 
improved understanding of medical diagnoses associated with the drug. 
The qualitative study by Snell, Langran, and Donyai (2017) investigated elderly patients’ 
perspective utilizing a questionnaire, for a pharmacist initiated, medication review addressing 
polypharmacy at the GP clinics.  The medication reviews prompted a total of 901 medications-
related changes (Snell et al., 2017).  The review and educational intervention was found helpful 
by 83% of respondents, with 80% expressing a better understanding of their medications, and 
94% stating medication-related concerns were addressed during the intervention (Snell et al., 
2017).  Limitations were only 51% of the eligible patients attended a medication review with  
only 40% of attendees completing a feedback questionnaire. Also, the longevity of the 
intervention was not evaluated.  Patients overwhelmingly perceived the medication reviews 
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positively.  The study reinforced the concept that patients’ understanding their medication is an 
important and crucial step in deprescribing and addressing polypharmacy among the elderly. 
Clinician competency and evidence-based deprescribing protocols. 
As exampled in the Martin et al. (2018) RCT, the importance of evidence-based 
deprescribing protocols for the prescriber was a consistent theme in the literature.  Primary care 
prescribers in the US have a vital role in the reduction of polypharmacy and PIMs, as well as the 
appropriate prescribing of PPOs.  Medication management and pharmacology are vital 
competences for medical trainees of multiple disciplines.  Learning to manage polypharmacy is a 
growing phenomenon in healthcare, which needs to first be addressed during the education of 
future prescribers (Kostas et al., 2014).  Early and regular exposure to the topic of polypharmacy 
and methods utilized to address the issue, are important to increasing confidence and competency 
of all clinicians during their journey to independent practitioner and beyond.  
A qualitative systemic review by Djerbib (2018) evaluated research studies related to the 
dynamics that influence the prescribing decision making process by primary care independent 
nurse providers (INPs) in the United Kingdom.  A total of 10 qualitative research studies were 
appraised for the systemic review, all meeting the inclusion criteria: INPs, primary care practice 
setting, prescribing decision-making, peer-reviewed, and studies performed in the United 
Kingdom.  The INPs identified three major themes that influence prescribing decisions: 
perception of competence, perception of risk, and impact on the patient.  Related to the 
perception of competence, there was a preference for use of evidence-based guidelines and 
formularies to facilitate decision-making.  The INPs identified patients with complex problems 
and polypharmacy to increase the risks of prescribing.  Impact on the patient was the third 
concern expressed by the INPs, involving adherence, clinical need for the prescription, and 
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patient costs.  In comparison to similar research on GPs, it was found that GPs also identified the 
same three major themes as influencing the prescribing process.  The research provides 
important insight to clinicians’ concerns related to competence, concerns for polypharmacy, and 
patient participation when prescribing, as well as a preference for the use of evidence-based 
guidelines.  The major limitation of the study was a single reviewer of the systematic review 
with a potential for bias and decreased transparency.  
In a quasi-experimental design study performed by Cossette et al. (2016), the aim was to 
evaluate the effects of a strategy using multiple interventions on the prescribing behaviors of 
physicians in the acute hospital setting.  The outcome of the research was an absolute decrease in 
PIMs usage of 3.5%, which showed significant decrease in physician prescribing of new PIMs 
(Cossette et al., 2016).  Interventions in the multi-strategy protocol included evidence-based 
educational material on PIMs targeted for non-introduction during hospitalization and 
educational presentation targeted to specific clinician groups.  Barriers identified to 
deprescribing were pre-hospital use of PIMs and lack of information for alternative non-
pharmacological or preferred/safer pharmacological options. 
The research study by Farrell et al. (2018) investigated whether the implementation of 
evidence-based deprescribing guidelines would increase the confidence of clinicians to actively 
reduce and stop medications that identified as PIMs.  The quasi-experimental design participants 
were physicians, nurse practitioners, and pharmacists both in long-term care facilities and family 
health practices.  Over the eighteen month study, the final analysis showed a significant, overall 
increase in clinicians’ confidence in deprescribing across multiple drug classes, when the 
guidelines were routinely utilized (Farrell et al., 2018).  Setting did affect outcomes with the 
clinicians in the long-term care facilities having the highest increases in confidence and action 
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related to deprescribing.  The most notable limitations in the Farrell et al. (2018) research, were 
the lack of psychometric testing of the instrument and low number of survey respondents. 
In the next study, the Beers Criteria was the basis for the implementation of a workshop 
with the goal to improve medical trainees confidence and ability to perform accurate medication 
reviews (Kostas et al., 2014).  The participants were internal medicine residents, physician 
assistant students, and geriatric fellows.  Participants first completed a needs assessment, which 
identified medications management and polypharmacy, as one of the five most important 
learning topics (Kostas et al., 2014).  Three months after attending the workshop 71% of 
participants reported making changes to patient medication regimens as a result of the 
information learned in the workshop (Kostas et al., 2014).  The major limitations were a pre-post 
survey quasi-experimental design, without a control group, conducted at a single site, and low 
participation rate in the follow-up survey (Kostas et al., 2014).  Even with these limitations, the 
improvement in the participants ability to identify appropriate medications for deprescribing, 
followed by taking action and making changes in the clinical setting, shows the strength of 
evidence-based deprescribing protocols in addressing polypharmacy. 
Research by Mecca et al. (2019) assessed the impact an educational intervention had on the 
knowledge and perceptions of internal medicine and nurse practitioner residents related to 
polypharmacy, complex medication management, and deprescribing PIMs.  The study was 
conducted at a veterans’ primary care clinic with an intervention and control group in a quasi-
experimental design study.  The intervention centered on a complete medication review with 
analysis using evidence-based tools, guidelines, and calculators to develop a deprescribing 
strategy.  Six months after the original intervention, both groups were given a post-test to 
evaluate polypharmacy knowledge.  The intervention group’s test scores averaged 14% higher 
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when compared to their pre-educational program test versus the control group’s 1.3% average 
post-test increase.  In addition, the intervention group perceived an improvement in knowledge 
and skills, and showed positive changes in the clinical setting demonstrated by an average of two 
discontinued medications for each veteran.  Study limitations were the small number of residents 
and no long-term evaluation of discontinued medications.  The research validates the consistent 
theme of clinician use of evidence-based deprescribing methods as an effective intervention to 
reduce polypharmacy, while building confidence and ability for improved care. 
The articles selected for the literature review provided a strong basis for reducing 
polypharmacy through appropriate prescribing of PIMs and PPOs.  The research reviewed 
included similar interventions implemented in both inpatient and outpatient settings, with 
positive outcomes independent of setting.  Involvement of all prescribing medical disciplines is 
vital to managing polypharmacy.  The studies demonstrated the initiation of evidence-based 
interventions with the specific aim to manage polypharmacy, have successfully raised clinicians’ 
awareness, competence, and confidence in implementing protocols for deprescribing.  Finally, 
encouraging patient involvement in the deprescribing process is an important component that 
needs to be considered by the prescriber for the successful of reduction of polypharmacy. 
Synthesis of Evidence 
The use of deprescribing is endorsed in the literature review as the key to addressing the 
problem of polypharmacy in elderly persons.  Deprescribing is described as the reduction, 
substitution or discontinuation of unnecessary or inappropriate medications (Kua et al., 2019).  
This theme was validated in other research.  Further delving into methods of deprescribing 
focused on medications identified as PIMs.  In addition, several of the research articles gave 
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equal importance to evaluating and correcting medications identified as PPOs, based on patient 
diagnoses.   
It was found deprescribing commonly followed a specific framework among the studies, 
starting with a comprehensive medication review and medical history including prescription and 
OTC drugs, supplements, and herbals.  Next, was the identification of PIMs, PPOs, and other 
medications to consider for discontinuation or modification of current dosage.  The questions 
asked to evaluate medications in this step included: did the patient have a medical indication for 
the drug; was the patient experiencing adverse effects; did potential harm outweigh benefits; did 
the medication provide therapeutic efficacy; and what were patient preferences.  Finally, the 
determination of medications to discontinue or change was made based on the previous criteria, 
the plan for stopping/changing medications was initiated, and monitoring support was provided 
in follow-up.  This deprescribing framework was generally employed in the research, to varying 
degrees, initiated by a prescribing provider, a multidisciplinary team of health care professionals, 
or a pharmacist medication review with recommendations to prescribers.  Consultation with the 
patient or a family member for input and preferences was also performed in some of the studies. 
There were several methods or interventions used to identify the PIMs, PPOs and other 
medications to discontinue or modify.  Included in these methods were the STOPP/START 
criteria, the American Geriatrics Society Beers Criteria, targeting specific drug classes (e.g. 
NSAIDs, benzodiazepines, diuretics, antidepressants, and neuroleptics), educational programs 
for prescribers and/or patients, and computer decision support systems.  The studies 
demonstrated these diverse methods to have various degrees of success in reducing 
polypharmacy through deprescribing.  But, not all methods studied were equally sensitive for the 
identification of PIMs and PPOs. 
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The majority of the literature indicates the reduction of polypharmacy and PIMs can 
decrease the risk of adverse events in elderly persons.  Among the negative consequences of 
polypharmacy are reduced ability to perform daily tasks, increased risk for cognitive impairment, 
delirium, falls, and urinary incontinence.  The research suggested the more medications a person 
uses regularly, corresponded with increased risk of drug interactions, emergency department 
visits, hospital readmissions, and a rise in mortality.  When measured, the studies imply an 
improved quality of life experienced with the reduction of polypharmacy and PIMs.  There was a 
wide variation in the measurement of adverse effects and positive outcomes, with multiple 
methods utilized to measure outcomes among the studies.  Evaluating the body of literature, 
multiple study outcomes were found positively affected by interventions used to deprescribe. 
Successful managing polypharmacy, realizes patient and family participation is an 
important component.  Patients may pressure providers to continue prescribing certain 
medications or a specific dosage, without a clear communication of medication changes.  Often 
patients don’t understand why they are on certain mediations, the reasons for a medication have 
resolved, or recognize a medication as the cause of an undesired side effect.  When patients or 
family were educated and actively involved in the deprescribing process, the results reflect 
improved understanding of medication changes and a significant decrease in polypharmacy.  
Acknowledging that physicians, nurse practitioners, and physician assistants are the 
primary care prescribers in the US, it follows the use of evidence-based deprescribing 
interventions in the primary care settings is crucial to addressing polypharmacy, PIMs, and 
PPOs.  Prescribing clinicians in all disciplines perceive medication management and the ability 
to address polypharmacy as vital skills for current and future practice.  The literature 
demonstrated that evidence-based deprescribing protocols incorporated into the primary care 
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setting is an effective method for continuing development of clinical judgment and clinician 
confidence necessary for appropriate prescribing and deprescribing of patient medications.  
Several methods for deprescribing were represented in the research and preferences by clinicians 
were shown to be relevant, focused and concise, user-friendly, evidence-based clinical tools.   
Conceptual Framework 
The conceptual framework used to guide the scholarly project was the Iowa Model of 
Evidence Based Care (Iowa Model Collaborative [IMC], 2017).  Permission was obtained from 
the University of Iowa Hospitals and Clinics as evidenced by materials contained in Appendix A.  
Adherence to the elements of the Iowa Model of Evidence Based Care ensured the successful 
implementation of the scholarly project.  The components addressed using the Iowa Model 
(IMC, 2017) were the identification of problems and triggers; the purpose of the intervention in 
addressing the phenomenon of interest; ensuring the topic was a priority to the organization; 
assembling a project team; the literature search and research critique supported the project; the 
development and implementation of the project; facilitated integration into practice change as 
appropriate; and dissemination of results.      
Triggers. 
Research showed polypharmacy contributed to frequent readmissions to the hospital, 
increased length of stay, adverse drug effects, risk of falls, physical and cognitive dysfunction, 
and mortality (Masnoon et al., 2017; Muth et al., 2018).  Evidence depicted clinicians at all 
levels of practice in need of methods to improve management of polypharmacy and competency 
in deprescribing (Djerbib, 2018; Farrell et al., 2018; Kostas et al., 2014; Mecca et al., 2019).  The 
research for the project has demonstrated the need for evidence-based guidelines in primary care 
clinics to improve polypharmacy management.   
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Purpose.  
The purpose of the project was to evaluate the effects the an evidence-based deprescribing 
tool had on prescribing clinicians’ confidence to address polypharmacy, PIMs, and PPOs in the 
primary care setting.  The intervention supported the decision-making process to perform 
appropriate prescribing and deprescribing activities.  The project increased skills and 
competency in the clinicians’ abilities to address polypharmacy and deprescribing. 
Organizational priority.  
The mission statement for Hillsdale Community Hospital (HCH) is “to provide quality, 
compassionate healthcare throughout the communities we serve” (Hillsdale Hospital [HH], 
2019).  The organizational values statement of HCH is “our commitment to you is Service 
Excellence... where the patient always comes first” (HH, 2019).  The scholarly project aligns 
with the mission and values of the organization with continued improvement in primary care 
through research-based methods, resulting in increased quality of care with a patient-centered 
experience. 
Formation of the team. 
The next step in the Iowa Model of Evidence Based Care (IMC, 2017) is the formation of a 
project team.  The team for the project is the project leader, the outpatient clinical coordinator for 
the hospital, clinical administrators, and the medical directors of the outpatient clinics.  This is 
the core group who made initial and ongoing decisions related to the project.   
Evaluation process and pilot. 
The Iowa Model of Evidence Based Care (IMC, 2017) next stage is the assembly, appraisal 
and synthesize of the body of evidence.  The evaluation of literature, found in Appendix B, 
provided evidence to support the scholarly project.  The literature review acknowledges the 
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problem of polypharmacy, use of clinical guidelines for reduction of polypharmacy, the need for 
medical management to address polypharmacy and deprescribing in the primary care setting, and 
the value of evidence-based deprescribing protocol in improving skills and confidence of 
prescribing clinicians.  The scholarly project was a pilot program to analyze the effectiveness of 
an evidence-based deprescribing tool on the clinicians’ perceived awareness and confidence to 
initiate medications changes.  The evaluation tool utilized was a pre-post survey of the 
prescribing providers that measured confidence levels in recognition of polypharmacy and 
decision-making in deprescribing.  
Summary 
The literature supported the use of deprescribing to address the problem of polypharmacy 
in the elderly population.  Although not consistent throughout, the majority of the literature 
found an association between deprescribing and decreased risk of drug interactions, adverse 
events, emergency department visits, hospital readmissions, and patient mortality.  When 
measured, most of the research validated deprescribing resulted in better patient outcomes.  
Methods that focused on reduction of PIMs demonstrated the most effective approaches to 
deprescribing and addressing issues related to polypharmacy.  
The importance of appropriate prescribing and evidence-based interventions that address 
polypharmacy were both topics shown to be important to prescribing clinicians of all disciplines 
(Farrell et al., 2018; Kostas et al., 2014; Mecca et al., 2019).  The research supported the need in 
various settings to implement protocols developed for evaluating polypharmacy and PIMs, that 
build knowledge, skills, competency, and confidence for deprescribing (Farrell et al., 2018; 
Kostas et al., 2014; Mecca et al., 2019).  Preferred methods were clinical tools that focus on user-
friendly and relevant material (Djerbib, 2018).  The evidence obtained through the literature 
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review supports the scholarly project, which is the implementation of a deprescribing protocol to 
improve skills and confidence in recognition of polypharmacy with the ability to make decisions 
to address deprescribing.  
Methodology 
Design 
The proposed scholarly project was an evidence-based practice, pilot project using the Iowa 
Model of Evidence Based Care (IMC, 2017).  The design of the project was a quasi-experimental 
approach with an evidence-based polypharmacy protocol designed to assist prescribing clinicians 
in the identification of PIMs and PPOs, and appropriate prescribing and deprescribing during 
primary care visits in the outpatient clinic setting.  The quasi-experimental design, although with 
limitations, was the design preferred when it is not ethical or logistically feasible to conduct a 
randomized control trial (Harris, McGregor, Perencevich, & Furuno, 2006).   
All participants received the deprescribing tool to be utilized during clinic visits with 
patients.  The goal of the project was to improve primary care providers’ confidence in 
addressing polypharmacy, PIMs and PPOs in the outpatient clinic setting.  The quasi-
experimental design planned, even with limitations, was expected to demonstrate a causal 
association between the intervention and outcomes.    
Measurable Outcomes 
After the receiving the deprescribing protocol and utilizing it with patients, prescribing 
clinicians were expected to demonstrate an increase in confidence rating on the Clinician 
Polypharmacy Management Survey (CPMS), after a 4 week period.  When comparing pre-
survey and post-survey scores, it was anticipated there would be a 10% increase in the 
prescriber's confidence for the deprescribing decision-making process to reduce polypharmacy.  
POLYPHARMACY INTERVENTION                      33 
The self-evaluation of the clinicians’ confidence in recognizing PIMs and PPOs was expected to 
reflect a 15% increase in the post-test.  The confidence ratings for the seven different barriers 
were anticipated to show variable increases when post-survey scores are compared to pre-survey.   
Setting 
The project setting was several outpatient clinics located in Hillsdale County, Michigan.  
The clinics are either owned by or closely associated with HCH.  The HCH health system serves 
the residents of Hillsdale and surrounding counties, with a wide range of inpatient and outpatient 
services.  The vision statement of HCH states, “As a leader in health services, HCH encompasses 
all of your healthcare needs utilizing state-of-the-art technology while embracing a future of 
organizational growth”, and the motto is “Large enough to be of service ... small enough to care” 
(HH, 2019).  The organization is committed to improving patient care and health through the 
application of evidence-based practices.  Providing patient-centered care, HCH serves a diverse 
patient population, at all levels of the health and wellness spectrum.  The letters of support in 
Appendix C, D, and E confirms organizational support for the scholarly project. 
Population 
 The population for the project was the HCH primary care clinic providers, comprised of 
physicians, nurse practitioners, and physician assistants.  All providers from the four primary 
care clinics were invited to participate.  In order to obtain additional participants, providers from 
two primary care offices closely affiliated with the HCH were also invited to join the project.  
There were a total of 15 possible participants.  The inclusion criterion was the clinician must 
have provided primary care at least 20 hours a week.  The exclusion criterion was voluntarily 
choosing not to participate in the project.  Completion of the informed consent form and pre-
intervention CPMS were required for participation in the project.  An example of the informed 
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consent form can be found in Appendix F.  The participants were assigned a random code to 
ensure confidentiality of information.  The name-code key was stored in a locked, fireproof safe, 
off-site.  
Ethical Considerations 
The Collaborative Institutional Training Initiative (CITI) training modules for human 
research ethics and compliance training available on the Liberty University Institutional Review 
Board (IRB) website have been completed by the project leader.  Certificates confirming 
completion can be found in Appendix G.  It is important before conducting any research studies 
involving human subjects, the researcher has received training to ensure an ethically designed 
scholarly project and the protection of the human participants involved.  The scholarly project 
was presented and approved by the assigned Liberty University project chair and the 
organizations invited to participate.  The project was submitted to the Liberty University IRB, 
and the IRB letter confirming project approval can be found in Appendix H.  Evaluation of the 
scholarly project by the IRB is vital to ensure the research is ethically acceptable, protects the 
rights and privacy of the participants involved, and is in compliance with federal regulations and 
laws.   
Information gathered through the CPMS tool was stored in an Excel spreadsheet coded 
only by the random number initially assigned to the participant, with no other identifying 
information.  The spreadsheet was password protected in addition to being stored on a laptop 
with password protection.  The surveys and informed consents were stored in a locked, fireproof 
safe.  Only the project leader has access to the spreadsheet and locked safe.  The surveys, 
informed consents, and name-number key will be destroyed three years after completion of the 
project. 
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Data Collection and Survey Tool. 
Basic demographic data was collected during the initial pre-intervention survey and 
includes clinic, professional title (physician, nurse practitioner, physician assistant), years in 
practice and practice setting (primary care or other).  The project leader developed the CPMS 
tool based on the clinical question and barriers to deprescribing identified in the review of 
literature (Djerbib, 2018; Farrell et al., 2018; Kostas et al., 2014; Mecca et al., 2019).  The 
purpose of the 10-item survey was to capture the participants’ perception of confidence when 
deprescribing to reduce polypharmacy, recognizing PIMs and PPOs, and confidence when faced 
with seven common barriers to deprescribing.  A 0-10 scale was utilized for each question in the 
CPMS tool to offer the participants a more precise definition of confidence level.  The survey 
was reviewed with other members of the project team to assure clarity of content, improving 
reliability, and validity. 
Participants completed the pre-intervention survey before the initial training on the use of 
the deprescribing protocol tool and distribution of the tool.  The survey took less than 10 minutes 
to complete by all participants.  The post intervention survey was distributed to the participants 
via email, four weeks after receiving the deprescribing protocol tool and returned to the project 
leader through return email.  The pre-survey and post-survey results were entered into the IBM 
SPSS Statistics 25 (IBM Corp., 2016) software for statistical analysis.  
Intervention 
The scholarly project intervention consisted of a polypharmacy protocol booklet and a brief 
educational session designed to instruct the prescribing clinician on the use of the protocol.  The 
educational presentation took approximately ten minutes.  The tool was an adaptation of the 
STOPP/START toolkit using the following sources for current evidence-based information: the 
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2019 American Geriatrics Society Beers Criteria®, UpToDate, and current practice guidelines 
from the American Diabetes Association, the American College of Cardiology, the American 
Heart Association, the Centers for Disease Control and Prevention, and the American College of 
Chest Physicians.  The final polypharmacy protocol booklet used in the scholarly project was a 
series of double-sided, laminated cards approximately 5.25 x 4 inches, bound with a loose-leaf 
ring in the upper left hand corner for ease of flipping to the desired information.  Including the 
reference information, there were a total of 6 flip cards composing the booklet.   
Timeline. 
The scholarly project action plan for the approval, initiation, implementation, and 
evaluation of the scholarly project is contained in the following table. 
Table 1. Scholarly Project Timeline 
 Anticipated Completion  
Action Item Date 
Final scholarly project proposal submitted  10/25/2019 
Proposal Defense  11/6/2019 
Submitted to Liberty University IRB 11/8/2019 
IRB Approval 11/22/2019 
Visit clinics providing education, collect pre-intervention survey 
data and distribute polypharmacy protocol 
Week of December 1st 
Start of data compilation 12/16/2019 
Final survey data collection complete Week of January 6th 
Statistical Analysis 2/15/2020 
Draft write up of scholarly project complete 2/17/2020 
Final write up of scholarly project complete  2/25/2020 
Send scholarly project to editor 2/25/2020 
Final defense PowerPoint completed 2/27/2020 
Final defense date 3/12/2020 
Complete final revisions and submit to Scholars Crossing 3/15/2020 
Disseminate information to stakeholders 3/26/2020 
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Feasibility analysis. 
The polypharmacy scholarly project has been successfully implemented at the HCH 
primary care clinics and associated clinics.  The project had the full support of the outpatient 
clinics’ medical director, clinical coordinators and participating clinicians.  The population of 
Hillsdale County over the age of 65 is 18% compared to 15.9% for the State of Michigan (HH, 
2019).  This larger percent of elderly adults is associated with an increased incidence of chronic 
disease and polypharmacy, providing the proper patient population for a successful 
implementation.   
The major cost of the project was the printing and materials used to produce the pocket-
sized polypharmacy protocol.  Materials and printing were less than $100 and provided by the 
project leader.  There were minimal risks in the implementation of the polypharmacy protocol.  
Use of the intervention did not replace the clinical judgment of the clinician and was initiated as  
a supplement to the decision making process during patient medication review.  There was 
greater risk associated with not performing a medication review process that can decrease 
polypharmacy and address the inappropriate prescribing of PIMs and PPOs.  The overall analysis 
of the scholarly project resulted in a neutral use of resources, increased confidence in primary 
care clinicians with the deprescribing process, and expected improvement in patient outcomes 
over time.  These factors made the scholarly project very feasible for implementation. 
Data Analysis 
Following IRB approval, project implementation was initiated in the clinics, and also 
marked the beginning of data collection for analysis.  The general characteristics of the project 
population were presented in a table format comprising the following information: clinic, 
professional title (physician, nurse practitioner, physician assistant), years in practice and 
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practice setting (primary care or other).  Statistical analysis of the CPMS tool results was 
produced utilizing IBM SPSS Statistics 25 (IBM Corp., 2019).  The dependent variable was the 
perceived awareness and confidence of the clinician to initiate medication changes to address 
polypharmacy through deprescribing.  The 10-question CPMS tool completed by clinicians, 
before and after the intervention, measured the dependent variable.  The independent variable 
was the polypharmacy protocol booklet and a brief educational session.  Only the participants 
who completed the pretest and posttest CPMS tool were included in the data analysis.  
The paired sample t-test was utilized to determine the effectiveness of the polypharmacy 
intervention.  The analysis examined the differences between pre-survey and post-survey results 
obtained from the CPMS tool.  Descriptive statistics included computed mean and standard 
deviation to describe the project outcomes and were displayed in table format.  Inferential 
statistics included paired samples correlation and confidence interval.  Inferential statistical 
results for each outcome measure were displayed in table format.  
Results 
The scholarly project was designed to assess if an evidence-based protocol for 
deprescribing increased clinician’s perceived awareness and confidence to address 
polypharmacy, PIMs, and PPOs in an outpatient clinic population.  Eight primary care providers, 
from five clinics, accepted the invitation to participate in the polypharmacy project.  The eight 
participants (n=8) completed the pre-intervention survey, received the deprescribing tool, and a 
brief training on how to use the tool in practice, at each clinic.  The post-intervention survey was 
sent to all eight participants by email four weeks after the office visits.  The post-survey was 
completed by seven participants (n=7), 87.5 % of the original participants, one participant (n=1) 
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declined to complete the post survey, resulting in a non-completion rate of 12.5%.  Table 1 
displays the scholarly project participant numbers during the pre-survey and post-survey.  
Table 2.  Polypharmacy Intervention Participation by Pre-survey and Post-survey 
Project Phase Completion Non-completion 
    Pre-Survey and Intervention 8 0 
    Post-Survey 7 1 
Response Rate Post-Survey (%) 87.5 12.5 
  
Descriptive Statistics 
Only the seven participants who completed both the pre-intervention and post-intervention 
surveys will be included in further data analysis.  Originally, the demographic information of the 
participants was to include clinic information.  Due to the reassignment of some participants to 
other clinics during the four weeks between the pre-survey and post-survey data collection, clinic 
of practice became irrelevant as a demographic.  The general characteristics of the project 
population are displayed in Table 2.   
Table 3.  General Characteristics of Project Participants 
Variable Frequency Percentage (%) * 
Professional Title   
     Physician 
      
1 14.3 
     Nurse Practitioner 
 
4 57.1 
     Physician Assistant 2 28.6 
Years in Practice   
     < 5 years 3 42.9 
     5-15 years 2 28.6 
     > 15 years 2 28.6 
Practice Setting   
     Primary Care  6 85.7 
     Primary Care and Walk-in Clinic 1 14.3 
*Response totals do not equal 100% due to rounding. 
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In order to better understand clinician’s perceptions of polypharmacy and the deprescribing 
tool, there were three standalone questions asked of each project participant.  One question was 
on the pre-intervention survey, asking if the clinicians perceived polypharmacy to be a major 
health care issue in their practice setting.  The other two questions were asked on the post-
intervention survey.  The first question inquired if the clinician used the deprescribing tool, and 
the second question, if the tool was helpful in the medication prescribing/deprescribing decision-
making process.  The majority of the clinicians, 85.7%, did perceive polypharmacy as a major 
health care issue in the practice.  One hundred percent of clinicians involved in the project did 
use the deprescribing tool and all found it to be useful in the decision making process of 
prescribing and deprescribing medications.  Table 3 presents the results of clinicians’ responses. 
Table 4.  General Perception of Polypharmacy Prevalence and Use of Deprescribing Tool 
Question Yes Percentage (%) No Percentage (%) 
Pre-intervention     
     Perceive polypharmacy to be a  
     major health care issue?  
6 85.7 1 14.3 
Post-intervention     
     Did you use the deprescribing  
     tool? 
7 100 0 0 
     Was the tool helpful in the 
     prescribing process? 
7 100 0 0 
 
The statistical analysis of the CPMS was performed utilizing IBM SPSS Statistics 25 (IBM 
Corp., 2019).  The paired samples t-test was applied to compare the differences in the pre-survey 
and post-survey scores for each of the ten questions answered by the participants.  The results 
presented in Table 4 are the statistical values for mean, standard deviation, and standard error 
means. 
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Table 5.  Paired Samples Statistics Analysis Organized by CPMS Question 
CPMS     Mean Standard 
Question No.  N Mean Std. Error Deviation 
1 Pre-survey 7 7.43 .649 1.718 
 Post-survey 7 8.00 .577 1.528 
2 Pre-survey 7 8.14 .634 1.676 
 Post-survey 7 8.43 .528 1.397 
3 Pre-survey 7 7.29 .680 1.799 
 Post-survey 7 7.71 .778 2.059 
4 Pre-survey 7 5.43 .528 1.397 
 Post-survey 7 6.00 .617 1.633 
5 Pre-survey 7 5.00 .535 1.414 
 Post-survey 7 5.14 .553 1.464 
6 Pre-survey 7 6.43 1.043 2.760 
 Post-survey 7 7.14 1.100 2.911 
7 Pre-survey 7 7.29 .680 1.799 
 Post-survey 7 7.43 .719 1.902 
8 Pre-survey 7 6.43 .751 1.988 
 Post-survey 7 6.57 .685 1.813 
9 Pre-survey 7 5.29 1.017 2.690 
 Post-survey 7 5.57 .997 2.637 
10 Pre-survey 7 6.71 .918 2.430 
 Post-survey 7 7.14 .911 2.410 
 
Measurable Outcomes 
The paired sample correlations are displayed in Table 5.  There is an individual analysis for 
each of the ten questions in the CPMS.  The strength of association between the pre-survey and 
post-survey variables, in all ten questions, was shown to have a strong positive correlation, with r 
values ranging from .886 to .984 and significance levels of .000 to .008. 
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Table 6.  Paired Samples Correlations by CPMS Question 
  
The main outcome expected from the intervention was an increase in the clinicians’ 
perceived confidence in the deprescribing decision making process.  This outcome was measured 
by question 1 on the CPMS, with a predicted increase of 10% from the pre-survey mean to the 
post-survey mean.  The pre-post mean difference for question 1 is -.571 (see Table 6).  This 
mean difference calculates to an increase of 7.7% using the pre-survey mean of 7.43 (see Table 
2).  Although there is an increase in confidence in the decision making process to deprescribe, it 
is less than the 10% predicted.  Further analysis of the Table 6 results for question 1 (t[7] = -
1.922 with a df = 6, p = .103 and 95% CI [-1.299, .156]), demonstrates the mean difference of -
.571 is not statistically significant.  
Two secondary outcomes expected of the project were an increase in clinicians’ confidence 
in the identification of PIMs and PPOs.  It was predicted the post-survey mean would 
demonstrate a 15% increase compared to the pre-survey results.  These outcomes were measured 
by questions 2 and 3 on the CPMS respectively.  Evaluating the identification of PIMs, a mean 
difference of -.286 is found for question 2 (see Table 6).  This mean difference reflects an 
CPMS     
Question No.  N Correlation (r) Sig. 
1 Pre-survey & Post-survey 7 .889 .007 
2 Pre-survey & Post-survey 7 .966 .000 
3 Pre-survey & Post-survey 7 .971 .000 
4 Pre-survey & Post-survey 7 .950 .001 
5 Pre-survey & Post-survey 7 .886 .008 
6 Pre-survey & Post-survey 7 .924 .003 
7 Pre-survey & Post-survey 7 .981 .000 
8 Pre-survey & Post-survey 7 .984 .000 
9 Pre-survey & Post-survey 7 .983 .000 
10 Pre-survey & Post-survey 7 .976 .000 
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increase of 3.5% using the pre-survey mean of 8.14 (see Table 2).  The increase in ability to 
identify PIMs is less than the 15% predicted.  Additional analysis of Table 6 results for question 
2 (t[7] = -1.549 with a df = 6, p = .172 and 95% CI [-.737, .166]), show the mean difference of -
.286 is not statistically significant.  The identification of PPOs utilizes the mean difference of -
.429 from question 3 (see Table 6).  The mean difference calculates as an increase of 5.9% when 
using the pre-survey mean of 7.29 (see Table 2).  This result, although demonstrating an 
increased ability to identify PPOs is less than the 15% predicted.  Further evaluation of Table 6 
results for question 3 (t[7] = -2.121 with a df = 6, p = .078 and 95% CI [-.923, .066]), show the 
mean difference of -.429 is not statistically significant.     
The remaining questions on the CPMS measure the confidence level of clinicians when 
encountering seven commonly identified barriers to deprescribing.  It was anticipated these 
secondary outcomes would reflect increased post-survey scores, but the results were expected to 
be variable and no percentage of increase was predicted.  The fourth question measured 
confidence in ability to deprescribe when the clinician was not the original prescriber of a 
medication.  The analysis of question 4 (Table 6) shows a significant average difference 
comparing pre-survey and post-survey scores (t[7] = -2.828 with a df = 6, and p = .030), and on 
average a post-survey scores were .571 higher pre-survey scores (95% CI[-1.006, -0.77]).  
Question 4 was the only measure on the CPMS tool to demonstrate statistical significance. 
Survey questions 5-10 measured confidence level of deprescribing for clinicians in the 
following situations, respectively: a specialist prescribed the medications, unsure why a 
medications was started originally, medication is used to treat adverse effect of another 
medication, the patient/patient’s family are resistant to change, medication is coupled to 
performance indicators, and concern for adverse drug effects or withdrawal.  The statistical 
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analysis of these six questions did demonstrate increases in post-survey scores compared to pre-
survey scores.  But as shown in Table 6 the increases are not statistically significant. 
Table 7.  Paired Differences by CPMS Question 
CPMS        
Question   Std. 95% Confidence    
No.  Std. Error Interval   Sig. 
Pre-Post Mean Deviation Mean Lower Upper t df (2-tailed) 
1 -.571 .787 .297 -1.299 .156 -1.922 6 .103 
2 -.286 .488 .184 -.737 .166 -1.549 6 .172 
3 -.429 .535 .202 -.923 .066 -2.121 6 .078 
4 -.571 .535 .202 -1.066 -.077 -2.828 6 .030 
5 -.143 .690 .261 -.781 .495 -.548 6 .604 
6 -.714 1.113 .421 -1.743 .315 -1.698 6 .140 
7 -.143 .378 .143 -.492 .207 -1.000 6 .356 
8 -.143 .378 .143 -.492 .207 -1.000 6 .356 
9 -.286 .488 .184 -.737 .166 -1.549 6 .172 
10 -.429 .535 .202 -.923 .066 -2.121 6 .078 
 
Discussion 
Implication for Practice 
The prevalence of polypharmacy within the healthcare system harms patient outcomes and 
costs patients and healthcare institutions tens of millions of dollars yearly (Masnoon et al., 2017; 
Quinn & Shah, 2017).  Polypharmacy, PIMs, and PPOs effect up to 50% of the elderly 
population and patients with two or more chronic diseases (Kua, 2019).  The clinicians involved 
in the project confirmed that polypharmacy was a major healthcare issue within the multiple 
practice settings.  The need for solutions to address polypharmacy through increased awareness 
and confidence of clinicians is an important subject for improvement of healthcare.  The findings 
of this project are consistent with the research indicating the need to address polypharmacy in 
everyday practice with the individual patient. 
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Decreasing polypharmacy through appropriate medication management involving clinician 
education and up-to-date evidence-based practice guidelines for prescribing and deprescribing in 
the practice setting, is supported by the literature (Djerbib, 2018; Kostas et al., 2014; Martin et 
al., 2018).  In the research, guidelines addressing polypharmacy frequently followed a specific 
framework and utilized a deprescribing protocol that was based on one or more of the many 
evidence-based prescribing guidelines (Campins et al., 2017; Clyne et al., 2016; Kua et al., 2019; 
Martin et al., 2018; Urfer et al., 2016; Van der Linden et al., 2017).  The polypharmacy protocol 
developed and used in the scholarly project was based on the proven framework and 
incorporated the most up-to-date evidence-based prescribing and deprescribing guidelines.  The 
protocol tool was designed with the intention for ease of use in the outpatient clinical 
environment.  All of the clinicians involved in the project used the polypharmacy protocol for 
prescribing and deprescribing in their practice.  In addition, all of the clinicians found the tool 
was helpful in the decision-making process of prescribing and deprescribing medications.  The 
project findings reinforced the importance of well designed, polypharmacy protocols based on 
evidence-based guidelines that is found in literature. 
Clinician education and evidence-based practice guidelines that focus on proper prescribing 
and deprescribing, have been shown in the research to improve awareness of polypharmacy and 
increase confidence in clinicians at all levels of experience (Djerbib, 2018; Farrell et al., 2018; 
Mecca et al., 2019).  The qualities of awareness and confidence are important to the process of 
addressing polypharmacy, including both inappropriately prescribed or omitted medications.  
The 10-question CPMS tool was used to evaluate clinicians’ awareness and confidence by 
comparing the results of the pre-post surveys.  The analysis of the CPMS tool scores 
demonstrated an increased overall awareness and confidence in all ten measures, although only 
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one measure was found to be statistically significant.  Even though not statistically signification 
and two of the predicted outcome measures were not reached, it is clinically significant that 
survey results revealed an increased confidence to reduce polypharmacy and ability to recognize 
both PIMs and PPOs prescribed to patients.  In addition, there was an increase in confidence 
level to deprescribe in each of the following situations: not the original prescriber of the 
medication, a specialist prescribed the medications, unsure why a medication was started 
originally, medication is used to treat adverse effect of another medication, the patient/patient’s 
family are resistant to change, medication is coupled to performance indicators, and concern for 
adverse drug effects or withdrawal.  The scholarly project demonstrated the effectiveness of the 
evidence-based polypharmacy protocol for increasing the awareness and confidence of the 
clinician in deprescribing. 
The most notable limitation of the scholarly project was four of the seven participants had 
the EPIC electronic health record in their practices.  The alerts, performance indicators linked to 
diagnoses, and clinical decision-making interfaces, all could have contributed to elevated self-
evaluation scores on the CPMS, especially on the pre-survey, taken before the introduction of the 
polypharmacy protocol tool.  The possible cause of an elevation of the pre-survey scores would 
have been related to the clinician’s confidence in EPIC’s ability to identify PPOs and 
contraindicated mediations.  Falsely elevated confidence scores on the pre-survey could 
potentially lead to post-survey confidence scores not representing the true increase.  Further 
studies could address this problem by introducing the polypharmacy protocol before the pre-
survey. 
A second limitation is the small sample size of the scholarly project.  The small sample 
size, n=7, can decrease the power of the statistical analysis, reducing the confidence level of the 
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project results.  A small sample size can affect the generalizability to another population or the 
repeatability in the same setting.  The third limitation is the four weeks between the pre-survey 
and the post-survey.  If the clinicians were given a longer period of time to use the protocol, 
three or six months, the results may have shown statistical significance (Farrell et al., 2018; 
Mecca et al., 2019).   
The limitations discussed are important.  Although only one of the ten measures was  
statistically significant and two of the three outcome measures were not met, the consistency of 
clinically significant positive results demonstrated in all ten measures, shows an increase in 
clinician confidence.  This increase in confidence experienced by the clinicians may create 
positive changes in practice with the potential to benefit both patients and the organizations 
through an improved level of care in the outpatient clinics. The results of the project agree with 
the literature that confidence to address polypharmacy can be increased through use of the 
evidence-based guidelines (Djerbib, 2018; Farrell et al., 2018; Mecca et al., 2019).   
Sustainability 
The five clinics that participated in the project are owned my three different entities that are 
either a part of, or associated with, HCH healthcare system.  The medical directors, clinic 
administrators, and participating clinicians have all expressed enthusiasm for the polypharmacy 
protocol.  The clinicians have also confirmed polypharmacy as a major healthcare issue within 
the practices and community.  Before the scholarly project proposal, addressing the substantial 
problem of polypharmacy within the healthcare system and clinics was not a focal point for 
improving patient care.  The initiation of the polypharmacy intervention into the practices has 
introduced an evidence-based solution for addressing polypharmacy beyond the scope of the 
electronic health records.   
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Evaluation of the scholarly project outcomes has provided information on the statistical and 
clinical significance of the polypharmacy protocol.  This information will be shared with the 
medical directors, clinic administrators, and participating clinicians.  This group will need to 
determine if the protocol is appropriate for integration across the clinics, or the current 
participating clinicians will continue using the tools.  The adoption of the intervention can be 
implemented with very limited resources.  These costs would include a yearly update to the tool 
utilizing the latest evidence-based guidelines and associated reprinting cost.  
Dissemination Plan 
The use of evidence-based guidelines for development of interventions to address 
polypharmacy, PIMs, and PPOs is supported by the critical appraisal of the literature.  The 
evaluation of the scholarly project by the medical directors, clinic administrators, and 
participating clinicians will determine the sustainability of the interventions and moving forward 
with the proposed execution of the dissemination plan.  If the decision is to move forward with 
further introduction and integration into the clinics, the project leader will partner with the clinic 
administrators to complete this task.  The project leader will present the polypharmacy protocol 
booklet with a brief educational session designed to instruct the prescribing clinicians on use of 
the protocol.  This introductory session will be completed at any additional clinics where the 
intervention is implemented.  If the clinic administrators wish to continue collecting data, the 
CPMS tool and Excel spreadsheet templates will be provided with documentation on usage.  The 
word document containing the polypharmacy protocol will be shared with the organization and 
training will be offered for maintaining the protocol with future evidence-based guidelines.  The 
completed, final scholarly project write-up will be published electronically in Liberty 
University’s Scholars Crossing.  
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The challenges encountered by this project leader while working on the scholarly project 
have been numerous.  Looking to our Father in Heaven, has sustained this project leader through 
this process.  Two Bible verses have helped with perseverance and served as a reminder of why 
this student is a nurse and importance of pursuing a DNP.  Philippians 2:4 (New International 
Version),  “Do not merely look out for your own person interests, but also for the interests of 
other” and Galatians 6:2 (New International Version), “Bear one another’s burdens, and thereby 
fulfill the law of Christ”. 
POLYPHARMACY INTERVENTION                      50 
References 
Campins, L., Serra-Prat, M., Gózalo, I., López, D., Palomera, E., Agustí, C., . . . on behalf of the 
REMEI Group. (2017). Randomized controlled trial of an intervention to improve drug 
appropriateness in community-dwelling polymedicated elderly people. Family 
Practice, 34(1), 36-42. doi:10.1093/fampra/cmw073 
Clyne, B., Cooper, J. A., Hughes, C. M., Fahey, T., Smith, S. M., OPTI-SCRIPT study team, & 
on behalf of the OPTI-SCRIPT study team. (2016). A process evaluation of a cluster 
randomised trial to reduce potentially inappropriate prescribing in older people in primary 
care (OPTI-SCRIPT study). Trials, 17(1), 386. doi:10.1186/s13063-016-1513-z 
Cossette, B., Bergeron, J., Ricard, G., Éthier, J., Joly‐Mischlich, T., Levine, M., . . . Brazeau, S. 
(2016). Knowledge translation strategy to reduce the use of potentially inappropriate 
medications in hospitalized elderly adults. Journal of the American Geriatrics 
Society, 64(12), 2487-2494. doi:10.1111/jgs.14322 
Djerbib, A. (2018). A qualitative systematic review of the factors that influence prescribing 
decisions by nurse independent prescribers in primary care. Primary Health Care, 28(3), 
25-34. doi:10.7748/phc.2018.e1355 
Farrell, B., Richardson, L., Raman-Wilms, L., de Launay, D., Alsabbagh, M. W., & Conklin, J. 
(2018). Self-efficacy for deprescribing: A survey for health care professionals using 
evidence-based deprescribing guidelines. Research in Social and Administrative 
Pharmacy, 14(1), 18-25. doi:10.1016/j.sapharm.2017.01.003 
Fried, T. R., O'Leary, J., Towle, V., Goldstein, M. K., Trentalange, M., & Martin, D. K. (2014). 
Health outcomes associated with polypharmacy in community‐dwelling older adults: A 
POLYPHARMACY INTERVENTION                      51 
systematic review. Journal of the American Geriatrics Society, 62(12), 2261-2272. 
doi:10.1111/jgs.13153 
Harris, A. D., McGregor, J. C., Perencevich, E. N., & Furuno, J. P. (2006). The use and 
interpretation of quasi-experimental studies in medical informatics. Journal of the 
American Medical Informatics Association, 13(1), 16-23. doi:10.1197/jamia.M1749 
Hillsdale Hospital. (2019). History. Retrieved from https:// www. hillsdale hospital. com/History 
IBM Corp. Released 2019.  IBM SPSS Statistics for Windows, Version 25.0.  Armonk, NY: IBM 
Corp. 
Iowa Model Collaborative.  (2017). Iowa model of evidence-based practice: Revisions and 
validation: Iowa model-revised.  Worldviews on Evidence-Based Nursing, 14(3), 175-182. 
doi:10.1111/wvn.12223 
Kimura, T., Ogura, F., Yamamoto, K., Uda, A., Nishioka, T., Kume, M., . . . Hirai, M. (2017). 
Potentially inappropriate medications in elderly Japanese patients: Effects of pharmacists’ 
assessment and intervention based on screening tool of older persons’ potentially 
inappropriate prescriptions criteria ver.2. Journal of Clinical Pharmacy and 
Therapeutics, 42(2), 209-214. doi:10.1111/jcpt.12496 
Komagamine, J., & Hagane, K. (2017). Intervention to improve the appropriate use of 
polypharmacy for older patients with hip fractures: An observational study. BMC 
Geriatrics, 17(1), 288-9. doi:10.1186/s12877-017-0681-3 
Kostas, T., Zimmerman, K., Salow, M., Simone, M., Whitmire, N., Rudolph, J. L., & McMahon, 
G. T. (2014). Improving medication management competency of clinical trainees in 
geriatrics. Journal of the American Geriatrics Society, 62(8), 1568-1574. 
doi:10.1111/jgs.12933 
POLYPHARMACY INTERVENTION                      52 
Kua, C., Mak, V. S. L., & Huey Lee, S. W. (2019). Health outcomes of deprescribing 
interventions among older residents in nursing homes: A systematic review and meta-
analysis. Journal of the American Medical Directors Association, 20(3), 362-372.e11. 
doi:10.1016/j.jamda.2018.10.026 
Löffler, C., Drewelow, E., Paschka, S. D., Frankenstein, M., Eger, J., Jatsch, L., . . . Altiner, A. 
(2014). Optimizing polypharmacy among elderly hospital patients with chronic diseases--
study protocol of the cluster randomized controlled POLITE-RCT trial. Implementation 
Science : IS, 9(1), 151-151. doi:10.1186/s13012-014-0151-7 
Martin, P., Tamblyn, R., Benedetti, A., Ahmed, S., & Tannenbaum, C. (2018). Effect of a 
pharmacist-led educational intervention on inappropriate medication prescriptions in older 
adults: The D-PRESCRIBE randomized clinical trial. JAMA, 320(18), 1889. 
doi:10.1001/jama.2018.16131 
Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A 
systematic review of definitions. BMC Geriatrics, 17(1), 230-10. doi:10.1186/s12877-017-
0621-2 
Mather, M., Jacobsen, L. A., & Pollard, K. M. (2015). Aging in the United States: Population 
Bulletin 70, no. 2.  Retrieved from https://www.prb.org/wp-content/uploads/2016/01/aging-
us-population-bulletin-1.pdf 
Mecca, M. C., Thomas, J. M., Niehoff, K. M., Hyson, A., Jeffery, S. M., Sellinger, J., . . . 
Brienza, R. (2019). Assessing an interprofessional polypharmacy and deprescribing 
educational intervention for primary care post-graduate trainees: A quantitative and 
qualitative evaluation. Journal of General Internal Medicine, 34(4) , 1-8. 
doi:10.1007/s11606-019-04932-9 
POLYPHARMACY INTERVENTION                      53 
Melnyk, B. M., & Fineout-Overholt E.  (2015).  Evidence-based practice in nursing & 
healthcare: A guide to best practice (3rd ed.). Philadelphia, PA: Wolters Kluwer Health. 
Muth, C., Uhlmann, L., Haefeli, W. E., Rochon, J., van den Akker, M., Perera, R., . . . Harder, S. 
(2018). Effectiveness of a complex intervention on prioritising multimedication in 
multimorbidity (PRIMUM) in primary care: Results of a pragmatic cluster randomised 
controlled trial. BMJ Open, 8(2), e017740. doi:10.1136/bmjopen-2017-017740 
Pasina, L., Brucato, A. L., Falcone, C., Cucchi, E., Bresciani, A., Sottocorno, M., . . . Nobili, A. 
(2014). Medication non-adherence among elderly patients newly discharged and receiving 
polypharmacy. Drugs & Aging, 31(4), 283-289. doi:10.1007/s40266-014-0163-7 
Potter, K., Flicker, L., Page, A., & Etherton-Beer, C. (2016). Deprescribing in frail older people: 
A randomised controlled trial. PLoS One, 11(3), e0149984. 
doi:10.1371/journal.pone.0149984 
Quinn, K. J., & Shah, N. H. (2017). A dataset quantifying polypharmacy in the United 
States.Scientific Data, 4, 170167. doi:10.1038/sdata.2017.167 
Schäfer, I., Kaduszkiewicz, H., Mellert, C., Löffler, C., Mortsiefer, A., Ernst, A., . . . Altiner, A. 
(2018). Narrative medicine-based intervention in primary care to reduce polypharmacy: 
Results from the cluster-randomised controlled trial MultiCare AGENDA. BMJ 
Open, 8(1), e017653. doi:10.1136/bmjopen-2017-017653 
Snell, R., Langran, T., & Donyai, P. (2017). Patient views about polypharmacy medication 
review clinics run by clinical pharmacists in GP practices. International Journal of Clinical 
Pharmacy, 39(6), 1162-1165. doi:10.1007/s11096-017-0538-z 
POLYPHARMACY INTERVENTION                      54 
Urfer, M., Elzi, L., Dell-Kuster, S., & Bassetti, S. (2016). Intervention to improve appropriate 
prescribing and reduce polypharmacy in elderly patients admitted to an internal medicine 
unit. PLoS One, 11(11), e0166359. doi:10.1371/journal.pone.0166359 
Van der Linden, L., Decoutere, L., Walgraeve, K., Milisen, K., Flamaing, J., Spriet, I., & 
Tournoy, J. (2017). Combined use of the rationalization of home medication by an adjusted 
STOPP in older patients (RASP) list and a pharmacist-led medication review in very old 
inpatients: Impact on quality of prescribing and clinical outcome. Drugs & Aging, 34(2), 
123-133. doi:10.1007/s40266-016-0424-8 
 
  
POLYPHARMACY INTERVENTION                      55 
Appendix A 
 
POLYPHARMACY INTERVENTION                                   56 
Appendix B 
Article Title, 
Author, etc. 
(Current APA 
Format) 
Study 
Purpose 
Sample 
(Characteristi
cs of the 
Sample: 
Demographics
, etc.) 
Methods Study Results 
Level of 
Evidence 
(Use Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? 
(Yes or No) 
Provide 
Rationale. 
Campins, L., 
Serra-Prat, M., 
Gózalo, I., 
López, D., 
Palomera, E., 
Agustí, C., . . . 
on behalf of the 
REMEI Group.  
(2017). 
Randomized 
controlled trial 
of an 
intervention to 
improve drug 
appropriateness 
in community-
dwelling 
polymedicated 
elderly people.   
To assess the 
effectiveness 
and safety of 
implementing 
a medications 
evaluation 
using the 
STOPP/ 
START tools.  
The study is 
for elderly 
persons living 
in the 
community, 
with 
polypharmacy 
of 8 or more 
medications. 
A convenience 
sample of 503 
recruited 
elderly patients 
within the 
community, 70 
years of age or 
older taking 8 
or more 
medications. 
Randomized, 
open-label, 
multicenter, 
parallel-arm 
clinical trial 
with follow- 
up.   
Findings 
indicate 26.5% 
of prescriptions 
were 
potentially 
inappropriate 
and 21.5% 
were changed.  
There was at 
least one 
change in 
95.6% of the 
intervention 
group.  The 
mean number 
of prescription 
per patient was 
significantly 
lower at 3, 6, 
and 12 months 
when 
compared to 
Level 2: 
randomized 
controlled 
trial 
Results were 
not evaluated 
blind.  Possible 
intervention-
to-control 
contagion, as 
the same 
physicians had 
patients in each 
arm of the 
study.  Sample 
size has limited 
statistical 
power for the 
secondary 
outcomes.   
Yes, 
evaluation of 
polypharmacy 
using an 
effective tool 
can 
successfully 
and safely 
reduce the 
burden and 
cost of 
polypharmacy 
to the patient.   
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the control 
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differences in 
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emergency 
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hospitalizations
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were observed. 
Clyne, B., 
Cooper, J. A., 
Hughes, C. M., 
Fahey, T., 
Smith, S. M., 
OPTI-SCRIPT 
study team, & 
on behalf of the 
OPTI-SCRIPT 
study team.  
(2016). A 
process 
evaluation of a 
cluster 
randomized 
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intervention 
execution, 
effectiveness, 
and preference 
of a three-
phase 
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inappropriate 
prescribing for 
the elderly in 
a primary care 
setting. 
A purposive 
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mixed 
method 
analysis with 
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structure 
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among the GP 
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participants as 
well as 
restrictive time 
allocated to the 
interviews.   
Yes, the 
research 
shows 
interventions 
aimed to 
decrease the 
number of 
inappropriate 
prescribed 
medications 
in the elderly 
is effective 
and 
achievable; it 
also 
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trial to reduce 
potentially 
inappropriate 
prescribing in 
older people in 
primary care 
(OPTI-SCRIPT 
study). 
more 
successful with 
patients 
present.  
Patient 
information 
leaflets were 
not used 
employed by 
any GP 
practice.  Both 
GPs and 
patients viewed 
the OPTI-
SCRIPT 
intervention 
positively. 
reinforces the 
importance of 
patient 
participation. 
Cossette, B., 
Bergeron, J., 
Ricard, G., 
Éthier, J., 
Joly‐Mischlich, 
T., Levine, M., 
. . . Brazeau, S. 
Evaluate the 
effects of a 
multiple 
interventions 
strategy on the 
prescribing 
behavior of 
A convenience 
sample of 8622 
patients, aged 
75 and older 
discharged 
from the 
hospital in 
A 
longitudinal 
pre-
intervention 
and post-
intervention 
experimental 
An absolute 
decrease of 
PIMs usage of 
3.5%. 
Interventions 
included: 
distribution of 
Level 3: 
quasi-
experimental 
design 
Implementatio
n of multiple 
interventions at 
different time 
points did not 
allow effects to 
be tracked 
Yes, this 
research 
identifies 
successful 
interventions 
used for the 
decreasing 
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(2016). 
Knowledge 
translation 
strategy to 
reduce the use 
of potentially 
inappropriate 
medications in 
hospitalized 
elderly adults.  
health 
professional.  
Each 
individual 
intervention 
has been 
shown to be 
effective in 
research 
literature.  
2013-2014.   design. educational 
material, 
presentation to 
targeted 
clinician 
groups, 
pharmacist 
presentations, 
computerized 
alerts, and 
comprehensive 
geriatric 
assessment. 
separately.  
Lack of home 
medication 
lists.  Effect on 
clinical 
outcomes not 
measured.  
Study was 8 
months and 
limits the 
evaluation of 
long-term 
effects. 
PIMs in the 
elderly patient 
in the 
hospital. 
Djerbib, A. 
(2018). A 
qualitative 
systematic 
review of the 
factors that 
influence 
prescribing 
decisions by 
nurse 
independent 
Establish and 
understand the 
dynamics that 
influence the 
prescribing 
decision-
making 
process of 
primary care 
nurse 
independent 
The sample is 
10 qualitative 
research 
studies of 
independent 
nurse providers 
in the primary 
care setting, 
who regularly 
prescribe as 
part of patient 
A systemic 
review of 
qualitative 
research 
studies 
matching the 
inclusion 
criteria of 
nurse 
independent 
prescribers, 
Three major 
themes 
emerged.  The 
first two 
themes are 
perception of 
competence 
and perception 
of risk.  Needs 
identified to 
increase 
Level 5: 
qualitative 
systemic 
review 
There was not 
a second 
reviewer to 
reduce the risk 
of bias and 
improve 
transparency. 
Yes, this 
research 
identifies the 
areas of 
perceived 
competence 
and risk as 
influential in 
the 
prescribing of 
independent 
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prescribers in 
primary care. 
providers. care.   primary care, 
prescribing 
decision-
making, 
peer-
reviewed and 
studies 
performed in 
the United 
Kingdom. 
competence 
and comfort 
level include: 
knowledge, 
skills, 
education and 
training, 
experience, and 
evidence-based 
guidelines and 
protocols.  The 
third theme is 
impact on 
patient, 
involving 
patient 
adherence, 
medical need, 
and costs. 
nurse 
providers.  It 
recognizes 
knowledge, 
education, and 
evidence-
based 
guidelines as 
methods used 
to improve 
competence.  
Finally, it 
considers the 
impact of 
prescribing on 
patients.   
Farrell, B., 
Richardson, L., 
Raman-Wilms, 
L., de Launay, 
D., Alsabbagh, 
Determine 
whether the 
implementatio
n of 
deprescribing 
A convenience 
sample, 
participants 
were 
physicians, 
A 
longitudinal 
pre-post 
deprescribing 
self-efficacy 
Longitudinal 
data showed 
the profound 
increase in self-
efficacy where 
Level 3: 
quasi-
experimental 
design 
Low number of 
survey 
respondents 
and lack of 
psychometric 
Yes, this 
study shows 
the use of 
evidence-
based 
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M. W., & 
Conklin, J. 
(2018). Self-
efficacy for 
deprescribing: 
A survey for 
health care 
professionals 
using evidence-
based 
deprescribing 
guidelines.  
guidelines 
would change 
the perception 
of self-
efficacy of the 
clinician. 
nurse 
practitioners, 
and 
pharmacists 
from 3 long-
term cares and 
3 family health 
teams.  Total 
participants = 
50. 
survey in a 
quasi-
experimental 
design. 
guidelines were 
routinely used. 
testing of the 
instrument. 
guidelines in 
deprescribing 
increase 
confidence 
and self-
efficacy.  
Fried, T. R., 
O'Leary, J., 
Towle, V., 
Goldstein, M. 
K., Trentalange, 
M., & Martin, 
D. K. (2014).  
Health 
outcomes 
associated with 
polypharmacy 
in 
Summarize 
health 
outcomes 
associated 
with 
polypharmacy 
in elderly 
community-
dwelling 
persons. 
The sample is 
50 
observational 
research 
studies of 
elderly persons 
in the 
community.  
The majority of 
the studies are 
identified as 
cross-sectional 
A systemic 
review of 
selected 
observational 
research 
studies. 
When 
polypharmacy 
was 4 or more 
medications 
there was more 
likely to be an 
association 
between 
measured 
outcomes and 
polypharmacy.  
Although 
Level 4: 
Cohort 
studies (there 
is not a higher 
level of 
evidence 
using Melnyk 
for a systemic 
review of 
cohort/case-
control 
studies) 
Heterogeneity 
in study 
populations 
and the 
definition of 
polypharmacy 
between 
studies made 
direct 
comparisons 
challenging.  
Many of the 
Yes, although 
there is a lot 
of 
heterogeneity 
between the 
studies, the 
association 
between 
polypharmacy 
and negative 
health 
outcomes is 
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community‐dw
elling older 
adults: A 
systematic 
review. 
or longitudinal 
cohort studies 
with 4 case-
control studies.   
results and 
outcomes 
studied varied 
per study, the 
majority of 
studies 
demonstrated 
relationships 
between 
polypharmacy 
and falls, fall 
outcomes, fall 
risk factors, 
adverse drug 
events, 
hospitalization, 
mortality, 
measure of 
function and 
level of 
cognition. 
studies were 
found through 
searching 
study reference 
lists; this may 
indicate the 
other relevant 
studies were 
missed.  Some 
of the studies 
were broad in 
medications 
prescribed, 
while others 
were not 
specific to 
excluded or 
included drugs 
or drug classes.   
strong when 
viewed in the 
overall 
context. 
Kimura, T., 
Ogura, F., 
Yamamoto, K., 
The efficacy 
of an 
assessment 
A convenience 
sample of 822 
inpatients aged 
A 
prospective 
observational 
A total of 346 
patients were 
prescribed 1 or 
Level 4: 
cohort study 
Study’s 
generalizability 
limited by one 
Yes, the 
research 
shows the 
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Uda, A., 
Nishioka, T., 
Kume, M., . . . 
Hirai, M. 
(2017).  
Potentially 
inappropriate 
medications in 
elderly 
Japanese 
patients: Effects 
of pharmacists’ 
assessment and 
intervention 
based on 
screening tool 
of older 
persons’ 
potentially 
inappropriate 
prescriptions 
criteria ver.2.   
and 
intervention 
by hospital 
pharmacists 
using the 
STOPP 
criteria related 
to potentially 
inappropriate 
prescriptions 
(PIMs) in 
elderly 
patients. 
65 or older. study from 
April 2015 to 
March 2016. 
more PIMs, 
310 PIMs were 
recommended 
to be 
discontinued, 
with a total of 
292 PIMs 
discontinued or 
changed related 
to the 
intervention. 
study site and 
the prescribing 
of PIMs drug 
classes may 
vary in 
different 
countries.  
Change in 
patient 
outcomes with 
use of the 
STOPP criteria 
was not 
evaluated.  
Reason for 
initial 
prescribing of 
PIM was not 
considered in 
intervention.  
 
prescribing of 
PIMs is a 
significant 
problem in the 
elderly, which 
needs to be 
addressed.  
The research 
also found 
PIMs can 
effectively be 
addressed 
using tools 
that are 
currently 
available. 
Komagamine, 
J., & Hagane, 
Evaluate the 
effectiveness 
A convenience 
sample of 164 
A 
retrospective 
The total 
number of 
Level 4: 
correlational 
The setting 
was a single 
Yes, the 
intervention 
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K. (2017).  
Intervention to 
improve the 
appropriate use 
of 
polypharmacy 
for older 
patients with 
hip fractures: 
An 
observational 
study.   
of an 
intervention to 
improve 
appropriate 
polypharmacy 
for elderly 
patients 
admitted to 
the hospital 
for hip 
fractures.   
patients 
admitted to the 
hospital for a 
hip fracture 
over a two-year 
period.  All 
were 65 years 
of age or older 
and prescribed 
5 or more 
medications at 
admission. 
observational 
study. 
potentially 
inappropriate 
medications at 
discharge was 
significantly 
lower in the 
intervention 
group 
compared to 
the control 
group.  No 
significant 
differences 
were observed 
in clinical 
outcomes, at 
the 6-month 
follow-up, 
when 
comparing 
intervention 
control groups.   
design - 
cohort study 
site.  
Observational 
study not a 
randomized 
controlled trial.  
Database 
information 
was used, with 
no direct 
contact with 
patient.  Those 
lost to follow-
up was high.  
Long-term 
outcomes are 
unknown.  
Adverse 
reactions to 
medications 
changes are not 
recorded. 
was 
successful in 
lowering the 
number of 
medications 
in the control 
group.  Other 
studies have 
shown 
improvements 
in multiple 
outcomes that 
were not 
measured in 
this study.  
Only looking 
at a special 
subset of 
patients for 
the 
intervention 
may dilute the 
real effect of 
the 
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intervention.   
Kostas, T., 
Zimmerman, 
K., Salow, M., 
Simone, M., 
Whitmire, N., 
Rudolph, J. L., 
& McMahon, 
G. T. (2014). 
Improving 
medication 
management 
competency of 
clinical trainees 
in geriatrics. 
Evaluation of 
workshop that 
improves 
medical 
trainees ability 
to perform 
accurate 
medication 
reviews that 
result in 
positive 
changes in the 
management 
of patients’ 
medication 
regimens. 
A convenience 
sample of 
internal 
medicine 
residents, 
physician 
assistant 
students, and 
geriatric 
fellows.  Total 
of 76 
participants in 
the workshop 
and follow-up. 
Quasi-
experimental, 
before-after 
intervention 
design, with 
survey  
The medication 
management 
workshop 
improved 
medical 
trainees’ 
ability to 
accurately 
perform 
medication 
review and 
ability to make 
appropriate 
medications 
changes using 
deprescribing 
protocols. 
Level 3: 
quasi-
experimental 
design 
The study 
design did not 
include a 
control group.  
Conducted at a 
single site.  
Low 
participation 
rate for the 
follow-up 
survey.  
Yes, medical 
trainees in 
multiple 
disciplines 
were able to 
identify 
appropriate 
medications 
for 
deprescribing 
and make 
changes in the 
clinical 
setting with 
the lessons 
learned in the 
workshop. 
Kua, C., Mak, 
V. S. L., & 
Huey Lee, S. 
W. (2019). 
Health 
outcomes of 
Evaluate 
deprescribing 
studies 
performed 
among the 
elderly 
The sample is 
41 randomized 
clinical studies 
conducted in 
nursing homes 
on elderly 
A systematic 
review and 
meta-
analysis of 
randomized 
control trials 
Medication 
review with 
directed 
deprescribing 
had significant 
benefits.  
Level 1:  
systemic 
review and 
meta-analysis 
of 
randomized 
Measureable 
clinical 
outcomes in 
areas such as 
falls and 
mortality in 
Yes, 
deprescribing 
was found to 
be an 
effective 
approach to 
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deprescribing 
interventions 
among older 
residents in 
nursing homes: 
A systematic 
review and 
meta-analysis.  
residents in 
nursing homes 
and the 
resulting 
clinical 
outcomes. 
patients  Overall 
deprescribing 
interventions 
reduced by 
59% the 
number of 
potential 
inappropriate 
medications. 
controlled 
trials 
several studies, 
limited the 
study’s ability 
to pool data 
and conduct 
meta-analysis.  
Many studies 
had short study 
periods and 
absence of 
blinding.  
There were 
also variations 
in reporting 
measures for 
the same 
outcome. 
reducing 
potentially 
inappropriate 
medications.  
Also, the 
methods in 
this study did 
not increase 
risks to the 
patients. 
Martin, P., 
Tamblyn, R., 
Benedetti, A., 
Ahmed, S., & 
Tannenbaum, 
C. (2018).   
Effect of a 
Compare the 
effect of a 
pharmacist-
led 
educational 
intervention 
versus 
There were 69 
community 
pharmacies 
with a total of 
489 recruited 
patients, aged 
65 or older.  
A pragmatic, 
cluster-
randomized 
clinical trail, 
with the 
pharmacy 
used as the 
At the six 
months, 43% 
of the 
intervention 
group was no 
longer 
receiving 
Level 2: 
randomized 
controlled 
trial 
Limited 
recruitment of 
patient using 
NSAIDs and 
1
st
 generation 
antihistamines.  
Guidelines 
Yes, even 
with the 
limitations of 
the study 
education of 
the patient 
and primary 
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pharmacist-led 
educational 
intervention on 
inappropriate 
medication 
prescriptions in 
older adults: 
The D-
PRESCRIBE 
randomized 
clinical trial.   
standard care 
for the 
reduction of 
inappropriate 
prescriptions.  
Community 
dwelling older 
adults and 
their 
physicians are 
the focus of 
the 
intervention.   
Each patient 
was prescribed 
one or more of 
4 specific 
Beers Criteria 
medication 
groups.   
unit of 
randomizatio
n. 
prescriptions 
for the 
inappropriate 
medication(s) 
compared with 
12% of the 
control group.  
No adverse 
events 
requiring 
hospitalization 
were reported. 
changes for 
treatment of 
type 2 diabetes 
calling for the 
discontinuation 
of glyburide, 
was a 
confounding 
factor.  
Pharmacists 
were 
inconsistent 
distributing 
evidence-based 
information to 
physicians.  No 
data collection 
for adverse 
effects not 
requiring 
hospitalization.  
Reasons for 
deprescribing 
were not 
care providers 
is a consistent 
theme in the 
literature.  
Also, 
deprescribing 
using the 
Beers Criteria 
has reliably 
demonstrated 
positive 
patient 
outcomes in 
the literature. 
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collected from 
patients or 
physicians.   
Mecca, M. C., 
Thomas, J. M., 
Niehoff, K. M., 
Hyson, A., 
Jeffery, S. M., 
Sellinger, J., . . . 
Brienza, R. 
(2019).  
Assessing an 
interprofessiona
l polypharmacy 
and 
deprescribing 
educational 
intervention for 
primary care 
post-graduate 
trainees: A 
quantitative and 
qualitative 
evaluation. 
Assess 
internal 
medicine and 
nurse 
practitioner 
residents’ 
knowledge of 
polypharmacy 
and 
perceptions of 
the 
interprofessio
nal education 
intervention – 
IMPROVE  
Total residents 
= 36, with 18 
in the 
intervention 
group and 18 in 
the control 
group. 
Veterans 
receiving care 
= 71.  Study 
performed in a 
Veterans 
Administration 
polypharmacy 
clinic. 
Prospective 
cohort 
controlled 
study without 
randomizatio
n.  
Intervention 
group had 
significant 
greater 
improvement 
on test scores, 
perceived 
improvement 
in knowledge 
and skills, 
noting positive 
change in 
practice in the 
clinical setting.  
The average 
number of 
medications 
discontinued 
per veteran was 
two. 
Level 3: 
quasi-
experimental 
design 
Small number 
of residents in 
the study.  
Selection bias.  
Safety of 
medication 
discontinuation 
long term was 
not evaluated. 
Yes, this 
study is 
consistent 
with the 
theme that 
education for 
deprescribing 
of medical 
trainees in 
multiple 
disciplines is 
an effective 
method to 
reduce 
polypharmacy 
and the 
importance of 
precepting by 
other 
professional 
to improve 
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care and build 
confidence. 
Muth, C., 
Uhlmann, L., 
Haefeli, W. E., 
Rochon, J., van 
den Akker, M., 
Perera, R., . . . 
Harder, S. 
(2018). 
Effectiveness of 
a complex 
intervention on 
prioritising 
multimedicatio
n in 
multimorbidity 
(PRIMUM) in 
primary care: 
Results of a 
pragmatic 
cluster 
randomised 
controlled trial. 
Investigate the 
effectiveness 
of a computer 
decision 
support 
system in 
general 
practice for 
improving 
appropriately 
prescribed 
medication in 
older patients 
with multiple 
morbidities. 
From 72 
general 
practices in 
Hesse, 
Germany a 
random 
sampling of 
505 cognitively 
intact patients, 
60 years of age 
or older, 3 or 
more chronic 
diagnoses 
requiring 5 or 
more long-term 
drug 
prescriptions. 
A pragmatic, 
cluster 
randomized 
control trial.  
Unit of 
randomizatio
n was the 
practice. 
Findings 
indicate the 
PRIMUM 
intervention 
had no 
significant 
effects patient 
prescriptions, 
functional 
status, or 
quality of life. 
Level 2: 
randomized 
control trial 
Definition of 
polypharmacy 
was arbitrary. 
The study was 
population 
based and 
response rate 
was low, 
limiting the 
generalizability 
of the study.  It 
was felt the 
outcome 
measures were 
more 
insensitive 
then expected.  
Because of the 
intense 
collection of 
data at every 
study visit, the 
Likely, in this 
study group 
there was 
already a high 
quality of life 
and functional 
status and 
there were 
few 
medications 
determined to 
be 
inappropriate.  
This study is 
still provides 
important 
outcomes to 
consider in 
the overall 
scope of the 
proposed 
project. 
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risk of the 
Hawthorne 
effect was 
potentially 
higher than 
normal. 
Pasina, L., 
Brucato, A. L., 
Falcone, C., 
Cucchi, E., 
Bresciani, A., 
Sottocorno, M., 
. . . Nobili, A. 
(2014). 
Medication 
non-adherence 
among elderly 
patients newly 
discharged and 
receiving 
polypharmacy.  
Identify 
adherence to 
medication 
regimen in 
elderly 
patients 
identified with 
polypharmacy 
after hospital 
discharge. 
A convenience 
sample of 100 
patient aged 65 
or older 
recently 
discharged 
from an 
internal 
medicine ward 
in Italy 
throughout 
2012. 
Non-
experimental, 
structured 
telephone 
interview. 
Non-adherence 
to medication 
regimens was 
55.1% at first 
follow-up (15-
30 days after 
discharge) and 
69.6% at 3-
month follow-
up.  Number of 
drugs 
prescribed at 
discharge was 
related to 
medication 
non-adherence.  
Only 28.1% of 
patients at the 
Level 6: 
qualitative 
study 
Small sample 
size.  The self-
reporting 
method of the 
interviews is 
likely to lead 
to 
overestimation 
of adherence.  
Lack of 
information 
concerning 
clinical 
outcomes. 
Yes, as it 
provides good 
data and 
rational for 
the 
simplification 
of drug 
regimens and 
the 
importance of 
patient 
understanding 
the reason for 
each 
medication 
prescribed.   
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first follow-up 
and 25.3% at 
the second 
follow-up 
understood the 
reasons for 
their 
medications. 
Potter, K., 
Flicker, L., 
Page, A., & 
Etherton-Beer, 
C. (2016). 
Deprescribing 
in frail older 
people: A 
randomised 
controlled trial.  
Reduction in 
the number of 
medications 
consumed by 
people living 
in a residential 
aged care 
facility. 
A convenience 
sample of 95 
people over the 
age of 65, 
living in 4 
residential aged 
care facilities 
in rural 
Western 
Australia  
A 
randomized 
control 
study, in an 
open trial 
using a 
parallel 
design 
Findings show 
of the 348 
medications 
targeted for 
deprescribing, 
207 
medications or 
59% were 
successfully 
discontinued. 
Level 2: 
randomized 
controlled 
trial 
Small sample 
size, an open 
design that can 
contribute to 
treatment bias. 
Yes, 
deprescribing 
in the frail 
elderly can be 
accomplished 
without 
adverse 
affects and 
health 
outcomes. 
Schäfer, I., 
Kaduszkiewicz, 
H., Mellert, C., 
Löffler, C., 
Mortsiefer, A., 
Ernst, A., . . . 
Demonstrate 
an 
intervention 
based on 
patient-
centered 
Randomly 
selected 
patients from 
those who 
accepted 
invitations after 
A two-arm 
cluster-
randomized 
control trial. 
There was no 
difference 
between the 
control and the 
intervention 
groups related 
Level 2: 
randomized 
controlled 
trial 
There is a 
slight patient 
selection bias 
regarding 
gender and 
specific 
Likely, but 
valuable 
information is 
found in the 
study. The 
intensity of 
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Altiner, A. 
(2018). 
Narrative 
medicine-based 
intervention in 
primary care to 
reduce 
polypharmacy: 
Results from 
the cluster-
randomised 
controlled trial 
MultiCare 
AGENDA. 
communicatio
n will reduce 
polypharmacy 
in the patient 
without 
negatively 
affecting the 
quality of life. 
meeting study 
criteria, across 
55 primary 
care practices 
in Germany for 
a total sample 
of 604 patients.  
Age 65-84 
years old with 
at least three 
chronic 
diagnoses. 
to a change in 
number of 
medications 
taken or quality 
of life 
indicators.  The 
intervention 
group was 
twice as likely 
to receive an 
analgesic over 
the course of 
the study as 
well as spend 
fewer days in 
the hospital.   
diagnosis 
groups.  
Compared to 
the average 
population, 
volunteers may 
have been 
more 
cooperative 
and have a 
higher 
satisfaction 
with their 
primary care.  
Consultations 
were not 
observed, so 
intervention 
implementatio
n may not have 
followed the 
protocol. 
the 
intervention 
(3 – 30 
minute 
consultations) 
does not 
necessarily 
reduce the 
number of 
medications 
taken.  
Although not 
a primary 
outcome, days 
hospitalized 
was found to 
be reduced in 
the 
intervention 
group.  
Snell, R., 
Langran, T., & 
Investigate 
patient views 
The sample is 
819 patients, 
A patient 
feedback 
The education 
was found 
Level 6: 
qualitative 
Only 51% of 
the patient 
Yes, even 
with the 
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Donyai, P. 
(2017).  Patient 
views about 
polypharmacy 
medication 
review clinics 
run by clinical 
pharmacists in 
GP practices.   
regarding a 
patient-
centered 
clinical 
pharmacist-
led 
polypharmacy 
medications 
review service 
incorporated 
within GP 
clinics. 
75 years of age 
or older with 
15 or more 
prescribed 
medications, 
served by one 
of 34 GP 
practices in 
southeast 
England. 
questionnaire 
was analyzed 
using 
thematic 
analysis and 
descriptive 
statistics. 
helpful by 83% 
of respondents, 
80% stated 
they 
understood 
their 
medications 
better, and 94% 
stating 
medication-
related 
concerns 
before the 
review had 
their concern 
addressed. 
design study eligible for a 
medication 
review 
attended, and 
of those 
patients, only 
40% filled out 
a feedback 
questionnaire.  
Views of the 
intervention 
were not 
measured for a 
longer period 
of time. 
limitations of 
patient 
response, 
patients saw 
medication 
reviews 
positively.  
Patient 
understanding 
of their 
medications is 
important step 
in 
deprescribing 
and 
decreasing 
polypharmacy 
Urfer, M., Elzi, 
L., Dell-Kuster, 
S., & Bassetti, 
S. (2016).  
Intervention to 
improve 
appropriate 
Assess the 
safety and 
efficacy of a 
prescriber 
checklist for 
reducing 
polypharmacy 
A convenience 
sample of 450 
patients aged 
65 or older, 
consecutively 
hospitalized in 
the internal 
Single-
center, 
intervention, 
quasi-
experimental, 
before-after, 
cohort study. 
The 
intervention 
was associated 
with a 22% 
reduction in 
PIMs 
prescribed at 
Level 4: 
correlational 
design - 
cohort study 
This study 
does not have 
the same 
strength of 
evidence as a 
randomized 
control study.  
Yes, an easy 
to use 
intervention 
checklist 
produced a 
significant 
reduction in 
POLYPHARMACY INTERVENTION                                   74 
Article Title, 
Author, etc. 
(Current APA 
Format) 
Study 
Purpose 
Sample 
(Characteristi
cs of the 
Sample: 
Demographics
, etc.) 
Methods Study Results 
Level of 
Evidence 
(Use Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? 
(Yes or No) 
Provide 
Rationale. 
prescribing and 
reduce 
polypharmacy 
in elderly 
patients 
admitted to an 
internal 
medicine unit.   
and 
inappropriate 
prescribing 
using the 
STOPP 
criteria as well 
as the START 
criteria to 
identify 
potentially 
inappropriate 
prescribing 
omissions. 
medicine 
wards, of a 
Swiss hospital.  
Patients were 
prescribed 5 or 
more 
medications at 
admission.  
The control 
group will be 
450 
consecutively 
admitted 
patients in the 
same wards, 
with the same 
characteristics, 
during the 
same time 
period the 
previous year. 
discharge.  
Although an 
overall 
decrease in the 
number of 
prescription 
medications at 
discharge 
occurred, it 
was less than 
the 20% 
hypothesized.  
The expected 
reduction in the 
risk of 
potentially 
inappropriate 
prescribed 
omissions at 
discharge did 
not occur. 
The 
generalizability 
of the study is 
questionable 
with execution 
at a single site. 
Rotation of 
Internal 
Medicine 
physicians to a 
different ward 
every 1-2 
months can 
skew results. 
the risk of 
PIMs at 
discharge, 
even with the 
study 
limitations. 
Van der 
Linden, L., 
Decoutere, L., 
Assess the 
effect of a 
pharmacist 
A convenience 
sample of 172 
patients 
A 
monocentric, 
perspective 
In the 
intervention 
group, more 
Level 3: 
quasi-
experimental 
There was no 
attempt to 
randomize the 
Yes, the safe 
reduction of 
prescribed 
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Walgraeve, K., 
Milisen, K., 
Flamaing, J., 
Spriet, I., & 
Tournoy, J. 
(2017). 
Combined use 
of the 
rationalization 
of home 
medication by 
an adjusted 
STOPP in older 
patients 
(RASP) list and 
a pharmacist-
led medication 
review in very 
old inpatients: 
Impact on 
quality of 
prescribing and 
clinical 
outcome.  
intervention 
using the 
Rationalize 
home 
medication by 
an Adjusted 
STOPP in 
older Patients 
(RASP) on 
inappropriate 
prescribing, 
polypharmacy
, and clinical 
outcomes. 
admitted to one 
of three acute 
geriatric wards 
in a university 
hospital in 
Flanders, 
Belgium. 
control trial. 
Assignment 
to control or 
intervention 
arm 
determined 
by ward. 
medications 
were 
discontinued 
by discharge, 
including 
PIMs, 
compared to 
the control 
group.  In the 
control group 
there was 
significant 
improvement 
in quality of 
life, decrease in 
emergency 
department 
(ED) visits and 
hospitalizations 
and no adverse 
health events. 
design ward 
assignment at 
admission.  
Follow-up of 
patients was 
limited to 3 
month for ED 
visits and 
hospitalization.  
The cause of 
ED visits was 
not tracked.  
The university 
hospital setting 
may not be 
generalizable 
to other acute 
care setting 
hospitals. 
medications 
in geriatric 
patients has a 
positive effect 
on the quality 
of life and a 
downward 
trend in 
emergency 
department 
visits. 
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168 South Howell Street | Hillsdale, Michigan 49242 
517-437-4451 |  www.   hillsdale hospital.   com 
 
 
November 26, 2019 
 
Attention: Institutional Review Board 
Liberty University 
Lynchburg, VA 
 
RE: Catherine Steiner’s Doctor of Nursing Practice Scholarly Project 
 
To Who It May Concern, 
 
Hillsdale Hospital Outpatient Clinics are committed to improving patient care and health 
through the application of the most up to date, evidence-based, best practices.  Ms. 
Catherine Steiner’s Doctor of Nursing Practice Scholarly Project: The Impact of an 
Evidence-based Protocol to Enhance Provider Awareness and Confidence in Addressing 
Polypharmacy in the Outpatient Setting aligns with our commitment and we are please to 
support this project pending Liberty University IRB approval.   
 
The outpatient clinics that will be eligible to participate in the project are:  Hillsdale 
Health & Wellness Clinic, Hillsdale, MI; Litchfield Health Clinic, Litchfield, MI; 
Reading Health Clinic, Reading, MI; and Three Meadows Medical, Hillsdale, MI. 
 
Please feel free to contact me for further assistance. 
 
Sincerely, 
 
Seth Gibson 
 
Seth Gibson, Administrator 
Outpatient Clinics 
Office:  517-439-2730 
Email: sgibson  @  Hillsdale  hospital.com 
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Hillsdale Medical Associates, PLC 
1456 Cross Street | Hillsdale, MI  49242 
Phone: 517-439-0200  
 
 
December 3, 2019 
 
Attention: Institutional Review Board 
Liberty University 
Lynchburg, VA 
 
RE: Catherine Steiner’s Doctor of Nursing Practice Scholarly Project 
 
To Who It May Concern, 
 
Hillsdale Medical Associates, PLC is committed to improving patient care and health 
through the application of the most up to date, evidence-based, best practices.  Ms. 
Catherine Steiner’s Doctor of Nursing Practice Scholarly Project: The Impact of an 
Evidence-based Protocol to Enhance Provider Awareness and Confidence in Addressing 
Polypharmacy in the Outpatient Setting aligns with the practice’s commitment and we are 
please to support this project pending Liberty University IRB approval.   
 
Please feel free to contact me for further assistance. 
 
Sincerely, 
 
Dan McCance, DO 
 
Dan McCance, DO 
Email: hmedicalassoc     @comcast.net 
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CONSENT FORM 
An Evidence-based Intervention to Enhance Provider Awareness and Confidence 
in Addressing Polypharmacy 
Catherine M. Steiner, NP 
Liberty University 
School of Nursing 
 
You are invited to be in a research study on increasing prescribing clinician’s awareness and 
confidence in addressing polypharmacy.  You were selected as a possible participant because 
you are a prescribing healthcare provider for patients in an outpatient clinic, either owned or 
affiliated with Hillsdale Hospital, and you work an average of 20 hours or more weekly seeing 
patients as their primary care provider.  Please read this form and ask any questions you may 
have before agreeing to be in the study. 
 
Catherine M. Steiner, a doctoral candidate in the School of Nursing at Liberty University, is 
conducting this study.  
 
Background Information: The purpose of this study is to determine if an evidence-based tool 
for deprescribing and appropriate prescribing can increase clinician awareness and confidence to 
address polypharmacy.  
 
Procedures: If you agree to be in this study, I would ask you to do the following things: 
1. Complete confidential pre-survey form.  This will take approximately 8 minutes  
2. Take part in an introductory session providing instruction on the use of the deprescribing 
tool.  Tool will be distributed at the beginning of the session.  This will take 
approximately 10 minutes. 
3. Complete confidential follow-up survey by email, 4 weeks after introductory session.  
This will take approximately 8 minutes. 
 
Risks: The risks involved in this study are minimal, which means they are equal to the risks you 
would encounter in everyday life. 
 
Benefits: The direct benefits participants may receive from taking part in this study are increased 
awareness and confidence in addressing polypharmacy through deprescribing and appropriate 
prescribing. 
 
Compensation: Participants will not be compensated for participating in this study.  
 
Confidentiality: The records of this study will be kept private.  Any published report will not 
include information that will make it possible to identify a subject.  Research records will be 
stored securely, and only the researcher will have access to the records.  Data will be stored in a 
password-protected file, on a password locked computer.  Completed surveys will be stored in a 
locked, fireproof, file cabinet located in the researcher’s private residence.  Data may be used in 
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future presentations, with the privacy of the participants maintained.  After three years, all 
electronic records will be deleted and original surveys will be shredded. 
 
Voluntary Nature of the Study: Participation in this study is voluntary.  Your decision whether 
or not to participate will not affect your current or future relations with Liberty University or 
Hillsdale Hospital.  If you decide to participate, you are free to not answer any question or 
withdraw at any time without affecting those relationships.  
 
How to Withdraw from the Study: If you choose to withdraw from the study, please contact 
the researcher at the email address/phone number included in the next paragraph.  Should you 
choose to withdraw, data collected from you, will be destroyed immediately and will not be 
included in this study 
 
Contacts and Questions: The researcher conducting this study is Catherine M. Steiner.  You 
may ask any questions you have now.  If you have questions later, you are encouraged to 
contact her at 517-290-8611 and/or csteiner4  @  liberty.edu.  You may also contact the 
researcher’s faculty chair, Dr. Ken Thompson, at kthompson55 @  liberty.edu. 
 
If you have any questions or concerns regarding this study and would like to talk to someone 
other than the researcher, you are encouraged to contact the Institutional Review Board, 1971 
University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or email at irb@liberty.edu.   
 
Please notify the researcher if you would like a copy of this information for your records. 
 
Statement of Consent: I have read and understood the above information. I have asked 
questions and have received answers. I consent to participate in the study. 
 
 
 
_____________________________________________________________________________ 
Signature of Participant        Date 
 
 
_____________________________________________________________________________ 
Signature of Investigator        Date 
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